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Multiple sclerosis (MS) is a chronic neuroinflammatory disease that is characterized 
by immune-mediated demyelination within the central nervous system. Nod-like 
receptor family pyrin domain containing 3 (NLRP3) inflammasome activation has 
been previously reported as a possible pathophysiological contributor to microglial 
activation and oligodendroglial loss in MS, particularly in progressive forms of the 
disease. Herein, it is demonstrated that etifoxine, a translocator protein (TSPO) 
ligand, attenuates the clinical symptoms in a mouse model of MS and significantly 
inhibits NLRP3 inflammasome activation in human and murine myeloid-derived cells 
in vitro by decreasing inflammasome-associated genes and inflammatory cytokine 
production. These anti-inflammatory effects of etifoxine were mediated independently 
of its previously described mechanisms related to engagement with TSPO and the 
GABAA receptor. Furthermore, we observed a similar anti-inflammatory effect of 
etifoxine on MS patient-derived monocytes, which provides clinical relevance for the 
investigation of etifoxine as a potential therapeutic in progressive MS. Lastly, through 
the use of a gene array, we identified multiple signalling pathways in order to 




Keywords: multiple sclerosis; TSPO; etifoxine; NLRP3; inflammasome; microglia; 
macrophage; TLR; therapy.  
 iii 
General Summary 
Multiple Sclerosis (MS) is a disease of the brain and spinal cord (central 
nervous system; CNS) that can cause disability. In MS, components of the immune 
system attack and cause dysfunction to parts of the CNS, which then impairs various 
aspects of a patient’s life, especially in relation to movement capabilities. 
Inflammasomes, which are a part of the immune response, have been identified as 
possible contributors to CNS dysfunction, especially in progressive MS. Herein, it is 
demonstrated that etifoxine, a drug that binds to the TSPO receptor on mitochondria, 
reduced the clinical symptoms in a mouse model of MS and significantly inhibits the 
inflammasome-mediated response in human and mouse derived immune cells. 
These anti-inflammatory effects of etifoxine were mediated independent of the 
presently known receptor targets for etifoxine, TSPO and GABAA. Furthermore, we 
observed a similar anti-inflammatory effect of etifoxine on MS patient-derived 
immune cells. Taken together, these findings provide clinical relevance to further 
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Chapter 1: Introduction 
1.1 Summary of Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous 
system (CNS) that is characterized by an infiltration of myelin-reactive CD4+ T cells 
(Guo et al., 2015) and a disease pathology that consists of inflammation, axonal loss, 
and neurodegeneration within the brain and/or spinal cord. Epidemiological research 
conducted by the Multiple Sclerosis International Foundation (2020) has indicated 
that MS affects twice as many females compared to males, with an average disease 
onset at approximately 30 years of age. As highlighted in the Atlas of MS 2020 
report, there are approximately 2.8 million people worldwide that are affected by MS 
(The Multiple Sclerosis International Foundation, 2020). The 2020 report also 
indicated that Canada currently has the third highest prevalence rate for MS, with 
250 people developing MS per 100 000 individuals.  
MS is a heterogenous disease with patients developing a wide range of 
neurological and/or physical symptoms as a result of the deterioration of the myelin 
sheath. The role of myelin is to insulate neuronal axons, which increases the rate 
and energy efficiency of action potentials, while decreasing the refractory period (The 
Multiple Sclerosis International Foundation, 2020; Boghozian et al., 2017; Garg & 
Smith, 2015). When myelin is damaged, symptoms arise in individuals that will 
eventually lead to a clinical visit and possibly an eventual MS diagnosis. These 
symptoms can be comprised of syndromes that are associated with neurological and 
cognitive deficits, such as muscle weakness/paralysis, spasticity, fatigue, 
depressive-like symptoms, temperature sensitivity, headaches, myelitis, and optic 
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neuritis (Lublin et al., 2014; Lublin & Reingold, 1996). MS can often be a highly 
debilitating disease, however, individuals that have received a diagnosis do not 
necessarily experience a shorter life span (The Multiple Sclerosis International 
Foundation, 2020). 
The revised 2017 McDonald Criteria is currently used to diagnose MS, (Polman 
et al., 2011; Thompson et al., 2018). In comparison to the previous version, the most 
recent version has included changes in regards to diagnosing MS based on: 1) the 
presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF), 2) a 
dissemination in space (DIS) and time (DIT) that can now be demonstrated by the 
presence of symptomatic lesions in patients with various syndromes, and 3) 
demonstrating DIS by the presence of cortical lesions (Polman et al., 2011; A. J. 
Thompson et al., 2018). The revised 2017 McDonald Criteria highlights the use of 
both magnetic resonance imaging (MRI) and CSF panels to demonstrate the 
presence of DIT and DIS in patients, and also to monitor disease progression. To 
demonstrate DIS by using MRI, a patient must exhibit one or more T2 lesions in two 
of the following four cortical areas: periventricular, juxtacortical, infratentorial, and the 
spinal cord (Swanton et al., 2007). In reference to the spinal cord, lesions are 
excluded if the patient already has a brainstem or spinal cord syndrome. DIT can be 
demonstrated using MRI, in which there must be at least one new T2 and/or 
gadolinium-enhancing lesion present on a follow-up MRI or a concurrent presence of 
asymptomatic gadolinium-enhancing and non-enhancing lesions (Miller et al., 2012; 
Montalban et al., 2010). CSF panels have also been utilized to aid in diagnosis 
(Thompson & Freedman, 2006), and are used to determine levels of immunoglobulin 
G (IgG) index and the presence of OCBs. While not yet used clinically, significant 
 3 
efforts have also been made to identify biomarkers, such as microRNAs, 
neurofilaments, and various macrophage and glial cell markers to aid in the 
diagnosis and monitoring of disease progression in MS. (Housley et al., 2015). 
Clinicians typically classify MS using three unique phenotypes or disease 
courses: 1) relapsing-remitting MS (RRMS), 2) secondary progressive MS (SPMS), 
and 3) primary progressive MS (PPMS). (Lublin et al., 2014; Lublin & Reingold, 
1996; Sand, 2015). RRMS may originally be diagnosed as a clinically isolated 
syndrome (CIS), which is defined as the initial clinical presentation of symptoms that 
are indicative of a demyelinating event (Polman et al., 2011; Sand, 2015). A CIS 
must meet the DIT MS diagnostic criteria in order to be further diagnosed as RRMS 
(Lublin et al., 2014; Lublin & Reingold, 1996; Polman et al., 2011). RRMS consists of 
acute attacks involving CNS dysfunction (i.e. a relapse) that partially or completely 
resolves (i.e. remission) (Lublin et al., 2014; Lublin & Reingold, 1996; Sand, 2015). In 
general, patients are stable during periods of remission and may not experience any 
neurological dysfunction. Unfortunately, however, the disease course can transition 
into a more progressive phenotype, which is termed SPMS (Garg & Smith, 2015; 
Gilmour et al., 2018; Lublin et al., 2014; Lublin & Reingold, 1996; Polman et al., 
2011; Sand, 2015). SPMS is predominately characterized by a gradual decline in 
neurological function, mainly in areas of the CNS that were previously impacted 
during relapses (Lublin et al., 2014; Lublin & Reingold, 1996). Lastly, PPMS consists 
of patients experiencing at least one year of progressive neurological dysfunction 
along with the presence of demyelinating lesions and/or OCBs in CSF (Sand, 2015). 
Despite the MS disease subtype, the clinical disease course is highly variable 
amongst individuals across all forms. While possessing several disadvantages, 
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including subjective bias, the extent of neurological impairment in MS is measured by 
the Kurtzke Expanded Disability Status Scale (EDSS) (Kurtzke, 1984), a scale 
ranging from 0.0 to 10.0, where an increased score is associated with greater 
neurological and physical impairment; a score of 10.0 signifies death as a result of 
MS (Kurtzke, 1984).  
The cause of MS is presently unknown, however, epidemiological and genome-
based studies have been conducted to determine disease risk factors and the 
presence of genetic predispositions. In some populations, there is evidence to 
suggest that mutations of the human leukocyte antigen (HLA) hla dr15/dq6, il2rA, 
and il7rA genes are inheritable risk factors for MS (Barcellos et al., 2003; Sawcer et 
al., 2011). Epstein-Barr Virus (EBV) positive individuals also have a higher incidence 
of MS; there is an extremely low incidence of MS in the EBV-negative population 
(Ascherio & Munger, 2008, 2007). There is also evidence to suggest vitamin D 
deficiency is highly correlated with an increased incidence of MS, while cigarette 
smoking is also considered a risk factor (Ascherio & Munger, 2008, 2007; Garg & 
Smith, 2015).  
Current disease modifying therapies (DMTs) are widely available for the 
treatment for RRMS, however, there are only very few options available for patients 
with SPMS and PPMS (Ciotti & Cross, 2018; Even, 2017). Major reasons for this are 
largely due to the inability to fully understand the pathology and/or etiology of 
progressive MS. At present, there is extensive and vast research currently being 
conducted to better understand the pathophysiology of progressive MS and identify 
possible pharmacological targets (Ciotti & Cross, 2018; Even, 2017). Multiple 
hypotheses have been proposed, including hypotheses suggesting that chronic 
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microglial activation during disease progression is the consequence of 
inflammasome-mediated activity (Ciotti & Cross, 2018; Govindarajan et al., 2020; 
Reynolds et al., 2012; Vidmar et al., 2019). The involvement of this proposed 
mechanism provides rationale to further explore the role of inflammasomes in both 
relapsing and progressive forms of MS. 
 
1.2 Involvement of Inflammasome Activation in General Disease Pathology 
Pattern recognition receptors (PRRs) are expressed on cells comprising the 
innate immune system (e.g. macrophages and monocytes) and are considered the 
first line of defence against infections and/or pathogens (Guo et al., 2015; Schroder 
& Tschopp, 2010a). NOD-like receptors (NLRs) are a class of intracellular PRRs that 
also recognize pathogen-associated molecular patterns (PAMPs) and danger-
associated molecular patterns (DAMPs). In several types of immune cells, albeit not 
exclusive to immune cells, inflammasomes are molecular complexes that become 
activated in response to cellular stress and pathogens. Presently, the most well-
characterized inflammasomes are NLR family pyrin domain containing 3 (NLRP3), 
NLR family CARD domain-containing 4 (NLRC4), and Absent in Melanoma 2 (AIM2) 
(Guo et al., 2015; Schroder & Tschopp, 2010a). Following activation, the primary 
function of the inflammasome is to induce inflammation and trigger an innate immune 
response, which results in immune cell recruitment by increasing blood flow and 
activation of the complement system (Dunkelberger & Song, 2010; Gandhi et al., 
2010; Koenderman et al., 2014; Schroder & Tschopp, 2010a). Complement is a 
complex system of proteins that once activated can enhance the immune response 
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by aiding in the destruction of pathogens and promoting inflammation (Dunkelberger 
& Song, 2010; Koenderman et al., 2014; Walport, 2001). In general, inflammasome 
activation occurs when procaspase-1 is recruited by an apoptosis-associated speck 
like protein containing a caspase recruitment domain (ASC/Pycard), which results in 
the cleavage and formation of active caspase-1 (He et al., 2016a; Jha et al., 2010; 
Martinon et al., 2002), which is depicted in figure 1. In the presence of danger and/or 
pathogen recognition, inflammasome activation typically results from extracellular 
adenosine triphosphate (ATP) influx and potassium efflux, lysosomal rupture, and/or 
mitochondrial dysfunction-derived signals, such as mitochondrial reactive oxygen 
species (mROS) or oxidized mitochondrial DNA (mDNA) (He et al., 2016b; Murakami 
et al., 2012). 
In most cell types, NLRP3 activation (figure 1) can occur through one of two 
signaling pathways:1) a canonical pathway and, 2) a non-canonical pathway (Coll et 
al., 2015; Pellegrini et al., 2017). The canonical pathway is characterized by two 
independent steps: transcription and oligomerization. The first step occurs through 
the TLR/MyD88/NF-kB pathway and results in the activation of pro-IL-1β and nlrp3 
transcription; the second step consists of NLRP3 oligomerization, which results in 
caspase-1 activation and subsequent release of IL-1β and IL-18 (Pellegrini et al., 
2017). Non-canonical inflammasome activation occurs in response to bacterial 
infections, such as E. coli and H. influenza induced infections (Huang et al., 2019; 
Vanaja et al., 2016). This type of inflammasome activation is dependent on caspase-
4/5 (caspase-11 in mice) and activates the TIR-domain-containing adapter-inducing 
interferon-β (TRIF)-dependent TLR4 pathway; activation of TRIF-dependent pathway 
results in NF-kB translocation, which in turn leads to the transcription of nlrp3 and 
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interferon regulatory factor 3 and 7 (irf3, irf7) (Loda & Balabanov, 2012; Shi et al., 
2014, 2015). The IRF3-IRF7 complex is responsible for activating caspase-4/5, 
which occurs when LPS enters the cytosol from endosomes and binds to caspase-
4/5 resulting in pyroptosis through gasdermin-D cleavage (McKenzie et al., 2018; 
Pellegrini et al., 2017; Shi et al., 2014, 2015; Taabazuing et al., 2017).  Monocytes 
can also display a form of alternative inflammasome activation, whereby the release 
of pro-inflammatory cytokines can occur in response to TLR activation alone, 
including TLR4 activation via lipopolysaccharide (LPS) (He et al., 2016a). 
As previously mentioned, a highly relevant class of PRRs in the context of 
inflammasome activation are the toll-like receptors (TLRs), specifically TLR4 
because of its ability to activate NLRP3 (Lucas & Maes, 2013; Peroval et al., 2013; 
Takeda & Akira, 2005; Yang et al., 2020). TLR4 is located on the surface of immune 
cells and primarily responds to varying types of bacteria. Once activated by a ligand, 
TLR4 can mediate signaling through either the myeloid differentiation factor 88 
(MyD88)-dependent pathway or the TRIF-dependent pathway (Su et al., 2018; Yang 
et al., 2020). MyD88 and TRIF are adaptor proteins; MyD88 pathway is essential for 
cytokine expression, while TRIF pathway activation is essential for interferon gene 
expression (Su et al., 2018; Yang et al., 2020). Regardless of the signalling pathway, 
TLR4 engagement will often activate NF-kB, a well-described transcription factor that 
stimulates the transcription of nlrp3 (Lucas & Maes, 2013; Ślusarczyk et al., 2018; 
Zheng et al., 2020). There is also evidence to suggest that inhibiting the 
TLR4/MyD88/NF-kB signaling pathway directly inhibits NLRP3 inflammasome 
activation and the downstream subsequent pro-inflammatory cytokine secretion (Lee 
et al., 2019; Ślusarczyk et al., 2018; Su et al., 2018).  
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The TLR4/MyD88/NF-kB signalling pathway can also function to regulate and 
differentiate T cells into either T helper-1 (Th1) or Th17 cells, which have both been 
demonstrated to play a pathogenic role in MS and experimental autoimmune 
encephalomyelitis (EAE), an animal model of MS (Qu et al., 2019; Reynolds et al., 
2010, 2012). Previous research has shown that EAE is completely ameliorated when 
CD4+ T cells are not able to express TLR4, likely because of a reduction in the Th17 
cell response (Reynolds et al., 2012). Furthermore, mice deficient in TLR4 did not 
experience any symptoms associated with EAE following induction, which further 
validates the modulatory role that TLR4 plays in inflammatory diseases (Zhang et al., 
2019). 
TLR4, as well as the NLRP3 and NLRC4 inflammasomes, has been identified as 
a potential contributor, biomarker, and/or therapeutic target in neurodegenerative 
and neuroinflammatory diseases. Genetic variants in inflammasome regulatory 
genes, such as nlrp1, nlrp3, and casp1 have also been recently identified as 
contributing factors to MS disease severity and phenotype, particularly PPMS, as 
well as the presence of genetic variants as an indicator of familial MS (Malhotra et 
al., 2020; Vidmar et al., 2019). There is evidence to suggest the involvement of 
NLRP3, NLRC4, and TLR4 in MS disease pathology (Beynon et al., 2012; Freeman 
et al., 2017; Govindarajan et al., 2020; Jha et al., 2010; Soares et al., 2019; Vidmar 
et al., 2019). Variants in the nlrp3 and nlrc4 genes have been identified and analyzed 
in MS to determine the presence of a functional role in disease severity and 
progression, specifically in regard to progressive disease phenotypes (Soares et al., 
2019). It was found that a gain-of-function mutation in the nlrp3 gene was associated 
with an overactive inflammasome activation response, therefore causing an 
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excessive secretion of pro-inflammatory cytokines, which was later determined to be 
a risk factor for disease severity (Soares et al., 2019; Verma et al., 2012). A loss-of-
function mutation in the nlrc4 gene was also identified, however, this variant was 
associated with a beneficial response in MS patients in regard to slower disease 
progression and a decrease in levels of IL-18 (Soares et al., 2019; Zeller et al., 
2015). 
 Furthermore, in vivo studies designed to measure the effects of NLRP3 
inhibitors and NLRP3 deletion in relation to inflammatory diseases have yielded 
promising results. MCC950 is a potent and highly specific NLRP3 inhibitor that has 
been used in animal models of inflammatory disease, such as EAE, as well as in 
murine and human derived myeloid cells in vitro (Coll et al., 2015; Hou et al., 2020). 
In EAE, treatment with MCC950 inhibited disease severity, improved cognitive 
functioning in the late phase of disease, and also maintained neuronal density in the 
hippocampus (Coll et al., 2015; Hou et al., 2020). Similarly, EAE mice lacking the 
nlrp3 gene had improved disease course and a delay in inflammation and 
demyelination within the CNS (Jha et al., 2010). These findings further suggest an 
important role for the NLRP3 inflammasome in neurodegenerative diseases that are 
driven by inflammation, such as MS. 
In Alzheimer’s disease, a neurodegenerative disease characterized by amyloid 
plaques and neurofibrillary tangles, there is also evidence to suggest a pathogenic 
role for inflammasome activation in disease progression and pathology (Coll et al., 
2015; Freeman & Ting, 2016; Yang et al., 2020). In microglia, TLR4 becomes 
activated by aggregated amyloid, which in turn stimulates a signaling cascade that 
ends with NLRP3 assembly and the release of IL-1β and IL-18, therefore contributing 
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to an increase in neuroinflammation and neurodegeneration (Lambert et al., 2013; 
McManus et al., 2014; Sims et al., 2017; Yang et al., 2020). This has been 
demonstrated in vitro whereby microglia were isolated from transgenic amyloid 
precursor protein/presenilin 1 (APP/PS1) mice, as well as by using genotyping to 
discover protein altering genetic changes in microglia that contributed to disease 
susceptibility (Lambert et al., 2013; McManus et al., 2014; Sims et al., 2017). 
Neuroinflammation is also known to drive disease progression in Parkinson’s, in 
which disease pathology consists of damage and the eventual death of dopaminergic 
neurons within the substantia nigra (Wang et al., 2019). It has been proposed that 
microglial NLRP3 activation is responsible for mediating a mechanism that stimulates 
the death of dopaminergic neurons, which has recently been explored in the 1-
methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model of Parkinson’s 
disease (Lee et al., 2019). MPTP mice that were NLRP3 deficient exhibited improved 
motor function and an increased abundance of dopaminergic neurons in the 
substantia nigra, suggesting that NLRP3 deficiency attenuates the symptoms and 
pathology associated with the MPTP model (Lee et al., 2019). The presence of Lewy 
bodies within the brain is also a pathological feature of Parkinson’s disease; 
aggregated α-synuclein (αSyn) is secreted as a result of neuronal damage, which 
then clusters to form Lewy bodies and leads to microglial activation (Croisier et al., 
2005; Wang et al., 2019). Furthermore, aggregated αSyn is processed as a danger 
signal by microglia, which can lead to NLRP3 inflammasome activation and 
subsequent neurodegeneration (Croisier et al., 2005; Haque et al., 2020; Lee et al., 
2019; Wang et al., 2019). These findings suggest that inhibiting NLRP3 may act as a 
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therapeutic target to decrease symptoms and slow the progression of Parkinson’s 
disease. 
In SPMS, TLR4 expression on CD4+ T cells was increased in patients that had a 
shorter RRMS disease course prior to transitioning to SPMS when compared to 
patients that had experienced a longer RRMS disease course (Manjili et al., 2020; 
Zastepa et al., 2014). These findings suggest a role for TLR4 signalling pathways in 
rapid disease progression and eventual disability associated with SPMS. The 
involvement of NLRP3, as well as TLR4, in MS disease pathology provides us with 
clinically relevant mechanisms that may be driving disease progression, and 
therefore further investigation may lead to the development of novel therapies for 
progressive MS. 
 
1.3 Overview of the 18 kDa Translocator Protein (TSPO)  
The 18kDa translocator protein (TSPO) is an evolutionarily-conserved protein 
complex that was first identified in 1977 and was initially named the peripheral-type 
benzodiazepine receptor (PBR) because of its high binding affinity for 
benzodiazepines (Bonsack & Sukumari-Ramesh, 2018; Braestrup & Squires, 1977; 
McNeela et al., 2018; Shoshan-Barmatz et al., 2019). In 2006, PBRs underwent a 
name change to TSPO because of its apparent involvement in protein transport 
and/or translocation within the cell (Papadopoulos et al., 2006). TSPO is expressed 
in all cell types in the periphery, as well as the nervous system, and is located on the 
outer mitochondrial membrane where it is primarily involved in shuttling cholesterol, 
the rate-limiting step of steroid synthesis (Airas et al., 2015; Bader et al., 2019; 
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Bonsack & Sukumari-Ramesh, 2018; McNeela et al., 2018; Papadopoulos et al., 
2006; Werry et al., 2019). TSPO has also been shown to play a role in mitochondrial 
metabolism, apoptosis, and inflammation (figure 1).  
 
Figure 1: TSPO Expression and Involvement in Inflammasome Activation 
 
TSPO is located on the outer mitochondrial membrane, in which it is involved in ROS 
production (Shoshan-Barmatz et al., 2019) which can then lead to subsequent 
inflammasome activation. TLR4 is located on the cell surface and reacts to bacterial 
products; engaging TLRP results in NF-kB activation. Following activation, NF-kB 
stimulates the transcription and expression of inflammasome-associated genes, such 
as nlrp3 (Lucas & Maes, 2013; Ślusarczyk et al., 2018; Zheng et al., 2020). 
ASC/Pycard then recruits procaspase-1, which results in the cleavage and formation 
of active caspase-1 (He et al., 2016a; Jha et al., 2010; Martinon et al., 2002). Active 
caspase-1 is then able to cleave and inherently activate the pro-inflammatory 
cytokines IL-1β and IL-18, which can then induce a form of inflammasome-mediated 
cell death termed pyroptosis. 
 
 
Created with BioRender™ 
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TSPO’s functionality in relation to inflammation has made it one of the most 
widely used targets for radioligands in positron emission tomography (PET) imaging 
(Airas et al., 2015; Alam et al., 2017; Dupont et al., 2017; Owen et al., 2017; 
Papadopoulos et al., 2006). Specifically, in neuroinflammatory diseases, the most-
well known tracer is PK11195. PK11195 is considered a first generation TSPO 
ligand, in which it was the initial compound to demonstrate a high affinity and 
selectivity for TSPO (Alam et al., 2017; Shehadeh et al., 2019; Venneti et al., 2007; 
Werry et al., 2019). The signal that is therefore increased in PET has been 
interpreted that PK11195 binds to TSPO in activated microglia and its signal is 
directly related to the level of inflammation. This interpretation has been recently 
challenged whereby increased TSPO expression has also been shown in activated 
astrocytes in situ within MS lesions (Nutma et al., 2019). In addition, upon activation, 
the level of expression of TSPO may indeed differ between species (Owen et al., 
2017),thus confounding the interpretation of the increased PET signal using TSPO 
ligands in the CNS, and questioning the biological relevance and significance of 
TSPO in the inflamed brain.  Over the past decade, several additional TSPO ligands 
have been developed as radiotracers to assess neuroinflammation (Cosenza-nashat 
et al., 2009; Chen & Guilarte, 2008; Rissanen et al., 2014; Veenman et al., 2007; 
Venneti et al., 2007), including PBR28, which has been documented to have a 80x 
increase in binding specificity for TSPO in comparison to PK11195 (Kreisl et al., 
2010, 2016; Nutma et al., 2019; Zürcher et al., 2015). PET imaging with PBR28 in 
Alzheimer’s patients displayed an increase in TSPO binding as the disease 
progressed over time, and in amyotrophic lateral sclerosis (ALS), variances in 
PBR28 uptake throughout the brain corresponded to differences in clinical ALS 
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phenotype (Kreisl et al., 2016; Zürcher et al., 2015). In MS, ligand binding of PBR28 
was evident in both microglia and astrocytes; one study showed that TSPO+ 
astrocytes made up approximately 25% of the TSPO+ cells in active and inactive 
lesion rims and 65% of the TSPO+ cells in the centre of both lesion types. A strong 
correlation observed between these TSPO+ cells and PBR28 binding (Nutma et al., 
2019). Furthermore, the ability to bind to activated astrocytes has only been recently 
documented in newer generation TSPO radioligands including PBR28 and XBD173 
(Dickens et al., 2014; Kaunzner et al., 2019; Nutma et al., 2019). These findings 
further suggest that TSPO-PET is a potential relevant biomarker in monitoring 
disease progression in multiple neuroinflammatory and neurodegenerative diseases. 
In MS, chronic microglial activation has been shown to be linked to the enhanced 
neurodegeneration that occurs in progressive disease states. TSPO-PET imaging 
allows for disease monitoring over an extended period of time and allows clinicians 
to follow primary disease progression because of its association with microglial 
activation and neurodegeneration (Airas et al., 2015; Nutma et al., 2019). As the 
disease phenotype transitions to a more progressive form, the neurological damage 
becomes inherently more diffuse, which has been shown to be related to the 
increased microglial activation occurring in SPMS (Cosenza-nashat et al., 2009; 
Chen & Guilarte, 2008; Rissanen et al., 2014; Veenman et al., 2007; Venneti et al., 
2007). Using TSPO-binding, radioligands in PET imaging can aid in understanding 
the disease pathology of SPMS in relation to microglial activation, and furthermore 
may even provide insight into the use of these radioligands as possible therapies for 
SPMS (Airas et al., 2015, 2018; Rissanen et al., 2014; Venneti et al., 2007).  
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Under normal physiological conditions, TSPO is not highly expressed in immune 
cells, such as macrophages and microglia, and other neural cells, including 
astrocytes. However, in response to injury, it has been suggested that when these 
cells become activated, expression of TSPO is increased (Cosenza-nashat et al., 
2009; Chen & Guilarte, 2008). Upon further investigation, there has been species-
specific differences in regards to the expression of TSPO when comparing murine- to 
human-derived myeloid cells (Owen et al., 2017). In murine myeloid cells, literary 
findings are consistent in displaying results that indicate an increase in TSPO protein 
levels and tspo gene expression under inflammatory conditions. In contrast, tspo 
gene expression was decreased in human myeloid cells under inflammatory 
conditions, which is suggestive of a species difference in regard to TSPO biology 
(Karlstetter et al., 2014; Owen et al., 2017; Wang et al., 2014). As previously 
mentioned, TSPO ligand binding is increased in areas of the brain that show an 
increase in inflammation, which was thought to be the result of activated microglia, 
however, in vitro findings in microglia indicate a decrease in tspo gene expression 
(Nutma et al., 2019; Owen et al., 2017; Sridharan et al., 2019). Taken together, 
further exploration is needed to fully understand the biological role of TSPO in 
neuroinflammation and how the TSPO-PET imaging data should be interpreted in the 
study of neurological diseases where microglia are involved (Airas et al., 2015; Alam 
et al., 2017; Dupont et al., 2017; McNeela et al., 2018; Nutma et al., 2019).  
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1.4 Etifoxine in the Central and Peripheral Nervous Systems 
Etifoxine (Stresam®) belongs to the non-benzodiazepine drug class and has 
been clinically used as a treatment for anxiety disorders in Europe, primarily France, 
and multiple South American countries (Poisbeau et al., 2018; Servant et al., 1998) 
(Gazzo et al., 2019; Nuss et al., 2019; Schlichter et al., 2000). As a previously 
discovered TSPO ligand, etifoxine has a high binding affinity for TSPO (Schlichter et 
al., 2000; Servant et al., 1998), but has also been shown to bind the ionotropic 
GABAA receptor (Mattei et al., 2019a; Schlichter et al., 2000). Etifoxine uses both 
direct and indirect GABA-mediated pathways to alleviate symptoms of anxiety 
disorders. Etifoxine binds directly to β - subunits of GABAA receptors, which 
influences synaptic transmission and enhances the inhibitory function of GABA 
(Poisbeau et al., 1997; Schlichter et al., 2000). Etifoxine also stimulates GABAA 
indirectly by binding to TSPO, which leads to an increase in neurosteroid and 
allopregnanolone production, and acts as a positive modulator of GABAA (Mattei et 
al., 2019a; Poisbeau et al., 1997, 2018; Schlichter et al., 2000). In addition, etifoxine 
has also been reported to modulate inflammatory responses in both the central and 
peripheral nervous systems, however, the mechanisms of action are presently 
unclear (Gazzo et al., 2019; Li et al., 2017; Simon-O’Brien et al., 2016). In various 
animal models of inflammatory-mediated disease, in both the CNS and the 
periphery, etifoxine treatment alleviated symptoms and improved disease outcomes 
(Daugherty et al., 2013; Li et al., 2017; Shehadeh et al., 2019). Initially, the majority 
of studies investigating the potential therapeutic effects of etifoxine were 
demonstrated in the periphery, such as sciatic nerve injury and mono-arthritis (Girard 
et al., 2008; Nuss et al., 2019). In the sciatic nerve injury model, rodents were 
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administered etifoxine following a cryolesion protocol with the goal of monitoring its 
effects on axonal regeneration and immune cell infiltration (Girard et al., 2008). 
Following nerve injury, etifoxine increased axonal regeneration and growth, 
decreased macrophage infiltration, and improved functional recovery. In a 
neuropathic pain model (complete Freund’s adjuvant (CFA)-induced model of mono-
arthritis) etifoxine reduced the overall symptoms associated with neuropathic pain 
(Aouad et al., 2014). In this model, it was also found that etifoxine treatment inhibited 
microglial activation and pro-inflammatory cytokine release in the lumbar spinal cord 
(Aouad et al., 2014), providing further evidence that etifoxine is capable of 
supressing the innate immune response. 
Aside from the periphery, etifoxine has also displayed promising effects in the 
CNS (Daugherty et al., 2013; Li et al., 2017; Ravikumar et al., 2016; Shehadeh et al., 
2019; Simon-O’Brien et al., 2016). In models of traumatic brain injury, etifoxine 
significantly reduced behavioural impairments, cortical lesion volume, microglial 
activation, neuronal degeneration, and pro-inflammatory cytokine release (Shehadeh 
et al., 2019; Simon-O’Brien et al., 2016). In EAE, administration of etifoxine following 
EAE induction decreased disease severity and improved recovery, while also 
decreasing peripheral immune cell infiltration and cytokine secretion (Daugherty et 
al., 2013; Ravikumar et al., 2016).  
The majority of the rationale supporting the anti-inflammatory effects of etifoxine 
has primarily pointed towards TSPO and its role in promoting neurosteroid 
production. Neurosteroids can modulate neuronal excitability and enhance GABAA 
mediated synaptic inhibition (Reddy & Estes, 2016), and have also been investigated 
as novel treatments for various CNS diseases that are characterized by GABAA 
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dysfunction, such as epilepsy, neuropathic pain, and mood disorders (Reddy & 
Estes, 2016; Schlichter et al., 2000; Verleye et al., 2005). In MS disease pathology 
specifically, progesterone and allopregnanolone have been shown to stimulate the 
expression of myelin protein genes in oligodendrocytes (Ghoumari et al., 2005; 
Ghoumari et al., 2003; Melcangi et al., 1999). Furthermore, the expression of 
allopregnanolone is decreased in MS patient white matter, which may be due to a 
decrease in upstream steroid converting enzymes resulting in impaired neurosteroid 
synthesis (Boghozian et al., 2017; Noorbakhsh et al., 2011, 2014). Even though 
neurosteroids have been implicated in MS disease pathology and possess an anti-
inflammatory and potentially regenerative role, a vital contributor to regulating 
neuroinflammation are microglia, which lack the CYP11A1 enzyme responsible for 
synthesizing steroids (Daugherty et al., 2013; Gaidt & Hornung, 2017; Owen et al., 
2017; Ravikumar et al., 2016; Shehadeh et al., 2019). It is therefore hypothesized 
that etifoxine modulates inflammation through a non-steroid related mechanism and 
serves as the rationale for the present work. 
 
1.5 Thesis Hypothesis and Objectives 
Prior findings have demonstrated that NLRP3 inflammasome activation, in both 
EAE and progressive MS, is responsible for neurodegeneration and disease 
progression  (Barclay & Shinohara, 2017; Freeman et al., 2017; Gris et al., 2010; 
Hou et al., 2020; Vidmar et al., 2019). As previously stated, etifoxine exhibits a 
potent anti-inflammatory effect in multiple animal models of disease, including EAE, 
which makes it a highly relevant option to explore as a potential therapy for MS 
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(Daugherty et al., 2013; Ravikumar et al., 2016). I hypothesize that a novel 
mechanism of action for etifoxine may be related to its ability to modulate 
inflammasome activation, which is thought to be a critical immune-mediated process 
that has been implicated in driving oligodendroglial death in MS (Loda & Balabanov, 
2012; McKenzie et al., 2018). Throughout this thesis, I explored three research aims: 
 
1. Determine whether etifoxine can influence inflammasome activation in 
vitro: 
Initially, preliminary studies were carried out in vivo to validate that etifoxine 
can decrease severity of EAE, an animal model of MS. In vitro, primary 
murine and human myeloid cells were used to determine the inhibitory effect 
of etifoxine on inflammasome activation. The expression of pro-inflammatory 
cytokines and inflammasome-associated genes were measured using ELISA 
and qPCR.  
 
2. Gain insight towards a mechanism of action and/or additional binding 
partner for etifoxine in vitro: After providing evidence that etifoxine 
exhibited an anti-inflammatory effect in vitro, we conducted a gene array in 
primary murine macrophages to further elucidate a molecular mechanism. 
The gene array was comprised of 86 inflammasome-associated genes, which 
were measured to assist in identifying potential binding partners and/or 
mechanism(s) of action for etifoxine. Experiments were also performed to rule 
out any direct TSPO-related or GABAA-related mechanisms.  
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3. Determine whether etifoxine could influence inflammasome activation 
on naïve (healthy) and activated SPMS-derived 
monocytes/macrophages: 
Lastly, to translate our findings and determine whether they were clinically 
relevant, pro-inflammatory cytokine expression was measured in SPMS 
patient-derived monocytes under inflammasome activating conditions, in the 
presence or absence of etifoxine.  
 
This thesis validates prior findings that etifoxine implements an anti-inflammatory 
effect both in EAE, as well as provides novel evidence that etifoxine modulates 
inflammasome activation in myeloid cells in vitro. Furthermore, I have shown that 
etifoxine has a similar anti-inflammatory effect in SPMS patient-derived monocytes, 
which provides clinical relevance of the utilization of etifoxine as a potential 
therapeutic target in progressive MS. Lastly, through the use of our gene array I have 
identified multiple pathways that etifoxine may be using to inhibit inflammasome 




Chapter 2:  Methods and Materials 
2.1 Mouse Primary Bone Marrow-Derived Macrophages 
Primary bone marrow-derived macrophages (BMDMs) were isolated from wild-
type C57BL/6 mice (Charles River). Mice aged 6 to 9 weeks were euthanized by CO2 
followed by cervical dislocation. 70% ethanol was used to disinfect the body of the 
mice and the hind limbs were removed at the hip flexor. The muscle and adipose 
tissue were carefully cut from the bone; the cleaned bones were then placed in 50mL 
conical tubes containing phosphate buffered saline (PBS), which was then placed on 
ice. Separate conical tubes were used for each individual mouse preparation, and 
instruments were sterilized with 70% ethanol between each dissection. Femurs and 
tibias were then placed in petri dishes (one per animal) and further cleaned via the 
use of a scalpel. Once there was no tissue remaining on the bones, the femur and 
tibia were separated via a cut at the knee joint and the ankle joint. A scalpel was 
used to further cut the tops and bottoms of the individual bones to expose the bone 
marrow. The bone marrow was expelled from the bones using a 21½ gauge needle 
and 1mL of PBS. The initial 1mL of PBS was used to flush out the marrow from the 
remaining bones for each animal. Bone marrow was transferred to a 15mL conical 
tube and 3mL of ice-cold 0.8% ammonium chloride (StemCell) was added to lyse red 
blood cells. The 15mL conical was then placed on ice for 5 to 10 minutes. 10mL of 
PBS was then added to dilute the ammonium chloride and the conical was 
centrifuged at 450 x g for 10 minutes at 4°C. The supernatant was removed and the 
cell pellet was resuspended in 2mL of macrophage media consisting of DMEM 
(Thermofisher/Life Technologies), 10% heat inactivated fetal bovine serum (HI FBS) 
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(USA Sourced, Corning, USA), 1x antibiotic/antimycotic (P/S) (Thermofisher/Life 
Technologies), 1x GlutaMAX (Thermofisher/Life Technologies), and 10ng/mL of 
Macrophage Colony-Stimulating Factor (M-CSF) (Cedarlane/Peprotech). 10µL of the 
cell suspension was then added to 90µL of trypan blue (Sigma Life Science) and a 
cell count was performed using a hemocytometer. Cells were plated at 5x105 
cells/mL in 10mL of macrophage media in a 10cm petri dish. After 3 days, an 
additional 5mL of macrophage media was added to the petri dish containing the 
cells. The cells were then plated in the experimental vessel after a total of 6-7 days. 
Plating macrophages involved removing the macrophage media that was currently 
on the cells and adding 5mL of ice-cold PBS. The petri dish was placed in the fridge 
for 15 minutes and a sterile cell lifter (Thermofisher/Life Technologies) was used to 
scrape the adhered cells from the bottom of the dish. The contents of the dish were 
transferred to a 15mL conical tube and centrifuged at 450 x g for 5 minutes. Cells 
were resuspended in 1mL of macrophage media (no M-CSF added) and recounted. 
The cell concentration was adjusted to 2.5x105 cells/mL, and cells were plated in the 
experimental vessel. After 1-2 days in culture, the cells were ready to use for 
experimentation. 
 
2.2 Mouse Primary Microglia 
The cortices of C57BL/6 mouse pups aged postnatal day 1 (P1) to postnatal day 
4 (P4) were dissected to obtain a mixed glia culture. Prior to dissection, the following 
solutions were made: Dissection solution (DS) consisted of 1x sterile Hank’s 
Balanced Salt Solution (HEPES) (Thermofisher/Life Technologies) and HEPES 
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(Sigma Life Science) with a final concentration of 10mM, which was then placed on 
ice for later use. Digestion solution consisted of 1mL 2.5% Trypsin (Thermofisher/Life 
Technologies), 2mL DS, and 0.05mg/ml DNAse 1 (Sigma Life Science); this volume 
of digestion solution is used for one culture (3 brains).  Lastly, astrocyte media 
consisting of DMEM, 10% HI FBS, 1x P/S, and 1x GlutaMAX was prepared and pre-
warmed in the 37°C water bath. Throughout the entire procedure, one culture is 
equivalent to three brains, and separate surgical instruments and solutions were 
used for each culture.  
Mouse pups were euthanized by decapitation and the brain was removed and 
placed in a sterile petri dish that contained approximately 5mL of DS. Forceps were 
used to gently remove the meninges from the cortex and the cortices were isolated 
and transferred into another petri dish containing DS. Sterilized scissors were used 
to cut the cortices into smaller pieces and a transfer pipette was used to move the 
pieces of cortices to a 15mL conical tube. One 15mL conical tube contained the 
cortices that were isolated from three separate mouse brains. DS was carefully 
removed from the 15mL conical tube (~9mL), 3mL of digestion solution was added, 
and the contents of the tube were triturated using a transfer pipette. The tube was 
nutated in a 37°C incubator for a total of 15 minutes and gently triturated halfway 
through the incubation period. 500µL of HI-FBS was then added to stop the digestion 
(i.e. inactivate the trypsin) and the tube was placed back on the nutator for an 
additional 5 minutes. The sample was centrifuged at 200 x g for 5 minutes at room 
temperature. After centrifugation, the supernatant was removed and the sample was 
resuspended in 5mL of pre-warmed astrocyte media. The sample was initially 
triturated with a cotton stuffed Pasteur pipette, followed by an 18-gauge blunt tipped 
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needle, and lastly by a 21-gauge blunt tipped needle to obtain a single cell 
suspension. The cells were passed through a sterile 70 µm strainer into a 50mL 
conical tube and centrifuged at 300 x g for 5 minutes. The supernatant was removed, 
and the sample was resuspended in 1mL of pre-warmed media. Following trituration, 
the cell suspension was brought to 12mL with pre-warmed media and then 
transferred to a T75 flask and placed in a 37°C incubator. The following day, a full 
media change was performed with pre-warmed media and a two-thirds media 
change was performed on day 3 and again on day 6. 
Microglia isolation occurred between days 10 and 14, depending on culture 
confluency. The standing incubator was pre-set to 37°C and the flask was shaken at 
200rpm for 1 hour. The media from the flask was transferred to a 15mL conical tube 
and centrifuged at 400 x g for 10 minutes at room temperature. Microglia were 
resuspended in 1mL of astrocyte-conditioned media and 10µL of the cell suspension 
was added to 90µL of trypan blue for counting. Cells were then plated at 2.5 x 105 
cells/mL in the experimental vessel(s). The microglia were used 3-5 days after 
plating. 
 
2.3 Experimental Autoimmune Encephalomyelitis  
Experimental autoimmune encephalomyelitis (EAE) was induced in accordance 
with the protocol described by Moore and colleagues (Moore et al., 2008). 24 hours 
after the first clinical signs appeared the mice were injected twice daily 
intraperitoneally with either vehicle (90% cyclodextrin, 10% ethanol), XBD-173 
(10mg/kg), or etifoxine (one 50mg/kg etifoxine, with saline as the second sham 
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injection) (Sigma Aldrich) for 7 consecutive days (Daugherty et al., 2013; Ravikumar 
et al., 2016). After 7 days of treatment, the mice were euthanized using sodium 
pentobarbital, transcardially perfused with sterile saline, and followed by cervical 
dislocation. Brains and spinal cords were removed for subsequent 
macrophage/microglia isolation (Pino & Cardona, 2010). 
Briefly, tissues were homogenized in RPMI using a dounce homogenizer to 
obtain a single cell suspension. Using a percoll gradient and various centrifugations 
and washes, the cells were collected at the 70%-30% gradient interface and MACS 
was performed on these cells using CD11b+ beads to obtain a pure population of 
microglia according to manufacturer’s protocols (Miltenyi). Cells were then stored in 
Trizol at -80°C. All EAE work was conducted by Dr. Craig Moore.  
 
2.4 THP-1 Macrophages 
Cryopreserved THP-1 monocytes (ATCC®) were thawed and cultured in media 
that consisted of RPMI 1640 (ThermoFisher/Life Technologies), 10% HI-FBS, 1x 
P/S, and 1x GlutaMAX. Monocytes were maintained at 5x105 cells/ml and stimulated 
with 20ng/ml of phorbal 12-myristate 13-acetate (PMA) (Sigma Aldrich) for 24 hours, 
which allowed the cells to adhere and differentiate into macrophages. After 24hrs, 
the cells were replenished with media and used for experimentation. All work 
involving THP-1 macrophages was conducted by Dr. Craig Moore. 
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2.5 Human Primary Monocyte-Derived Macrophages 
Human monocyte-derived macrophages (MDMs) were cultured from venous 
whole blood. All studies that involved human samples followed Canadian Institute of 
Health Research (CIHR) guidelines and institutional review board approval at 
Memorial University of Newfoundland (Health Research Ethics Authority). Peripheral 
blood was collected from healthy donors in EDTA-coated tubes following informed 
consent. Blood was placed on the nutator at room temperature while preparing for 
cell isolation. The following solutions were made: Macrophage media consisted of 
RPMI 1640, 10% HI-FBS, 1x P/S, 1x GlutaMAX, and 25ng/mL of M-CSF. MACS 
buffer was used for cell separation and consisted of 500mL sterile 1x PBS, 2mL of 
0.5M EDTA, and 2.5mL of HI-FBS. Blood was pooled from two 10mL BD 
VacutainerⓇ tubes into a 50mL conical tube. Tubes were then rinsed with sterile 
PBS and the remaining contents were emptied into the 50mL conical tube. The 
conical tube was filled with 1x PBS to a total volume of 35mL. SepMate™ tubes 
(StemCell Technologies) were used to isolate peripheral blood mononuclear cells 
(PBMCs). 15mL of Ficoll-Hypaque (ThermoFisher/Life Technologies) was added 
directly through the hole in the SepMate™ tube, next the 35mL blood/PBS mixture 
was slowly added to the tube via the use of a 25mL serological pipette. The 
SepMate™ tube was centrifuged at 1200 x g for 10 minutes (brake on) to separate 
the contents of the tube. The entire top layer (~35mL) was poured into a 50mL 
conical, which was then filled to 50mL with 1x PBS. The cells were centrifuged at 
300 x g for 15 minutes. The supernatant was poured off and the pellet was 
resuspended in 20mL of MACS buffer; an aliquot was taken and diluted at 1:2 in 
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Trypan Blue to determine the number of cells. The sample was then brought to 50mL 
with MACS buffer and centrifuged at 300 x g for 10 minutes. The supernatant was 
poured off and the cells were resuspended in 80µL of MACS buffer/1x107 cells. 20µL 
of anti-CD14+ (Miltenyi Biotec)/1x107 cells was also added to the sample, which was 
then mixed and incubated at 4°C for 15 minutes. During the incubation period, the 
MACS column was rinsed with 3mL of MACS buffer. After 15 minutes, the sample 
was washed with 20mL of MACS buffer and centrifuged at 300 x g for 10 minutes. 
The supernatant was poured off and the cells were resuspended up to 1x107 cells/mL 
of MACS buffer. The cell suspension was poured into the column and flow through 
was collected in a 15mL conical tube. The column was washed with 3mL of MACS 
buffer 3 consecutive times; the flow through was discarded. The column was 
removed from the magnet and placed on a new 15mL conical tube. 5mL of MACS 
buffer was added to the column and quickly plunged to expel the CD14+ antibody-
bound cells. A cell count was conducted, the final volume was brought to 15mL with 
MACS buffer, and the sample was centrifuged at 300 x g for 10 minutes. Cells were 
then resuspended in macrophage media and plated in desired experimental vessels 
at 5x105 cells/mL. After 2-3 days a half media change (RPMI 1640, 10% HI-FBS, 1x 
P/S, 1x GlutaMAX, and 25ng/mL of M-CSF) was performed, and the cells were used 
for experimentation 3-4 days later.  
 
2.6 Human Primary Fetal Microglia 
Human microglia were isolated from fetal CNS tissue obtained from consenting 
donors (Health Sciences Centre – General Hospital, St. John’s, NL). Prior to 
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dissecting the culture media was made and pre-warmed in a 37°C water bath. 
Culture media consisted of DMEM, 5% HI-FBS, 1x P/S, and 1x GlutaMAX. The CNS 
tissue dissection was performed using a stereomicroscope and sterilized surgical 
instruments. Sections of the brain and/or spinal cord were isolated and transferred to 
a 15mm petri dish containing sterile saline. The meninges were removed via the use 
of sterile forceps, and the tissue was transferred to a 15mL along with 2mL of sterile 
1x PBS, 1mL of 2.5% Trypsin, and 200µL of DNase. The sample was triturated with 
a 1000µL pipette and was then incubated at 37°C for 15 minutes on a nutator. 
Following the incubation period, 1mL of HI-FBS was added to the sample, which was 
then triturated and passed through a 70µm filter into a 50mL conical. The filter was 
rinsed with 1x PBS and the sample was centrifuged at 300 x g for 10 minutes at 4°C. 
The supernatant was removed, the sample was resuspended in 5mL of warmed 
culture media and then centrifuged at 300 x g for 10 minutes. Following 
centrifugation, the supernatant was removed, and the sample was resuspended in 
4mL of culture media, which was then transferred to a T12.5 flask. Fetal microglia 
were isolated and cultured according to the protocol by Durafourt and colleagues 
(Burguillos, 2013). 
 
2.7 HITMS Patient-Derived Primary Monocyte-Derived Macrophages 
All participants had provided written consent to be enrolled in the HITMS project 
at Memorial University of Newfoundland. The patient demographics have been 
described in Tables 5 and 6 (Sections 3.12 and 3.13). All studies that involved 
human samples followed Canadian Institute of Health Research (CIHR) guidelines 
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and institutional review board approval at Memorial University of Newfoundland 
(Health Research Ethics Authority).  
PBMCs were isolated from whole blood in accordance with the protocol 
described above (Section 2.5), after performing the cell count monocytes were 
isolated from PBMCs or whole-PBMCs were cryopreserved. Monocyte (CD14+ cell) 
isolation was performed according to the MACS separation protocol above (Section 
2.5). To differentiate the monocytes into macrophages, media comprised of RPMI, 
10% HI-FBS, 1x P/S, 1x GlutaMAX, and 25ng/mL of M-CSF was used. To culture 
monocytes, similar media was used, however, no M-CSF was added and the cells 
were cultured upright in a 15mL conical tube with a vented cap.  
Cryopreservation was conducted by resuspending the cells in ice-cold PBMC 
storage media, which consisted of 80% HI-FBS and 20% Culture Media (RPMI, P/S, 
1x GlutaMAX). An equal volume of ice-cold freezing media, which consisted of 70% 
HI-FBS, 10% Culture Media, and 20% DMSO, was slowly added to the sample and 
gently mixed.  1.0 mL aliquots of the cell suspension were then distributed into 
cryovials that were placed in a room temperature cryofreezing container, which was 
then stored at -80°C overnight. The cryovials were then transferred to liquid nitrogen 
for long-term storage. The patient information and corresponding cell count were 
updated in the HITMS database. All monocyte associated work was conducted by 
Dr. Craig Moore. 
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2.8 Inflammasome Activation and Etifoxine Treatment  
Inflammasome activation was conducted in the various cell types described 
above (2.1 – 2.5). Initially, a media change was performed on the cells that were 
being treated, thus the following protocol was conducted in a serum-free 
environment (DMEM or RPMI, 1x P/S, 1x GlutaMAX). Once in serum-free media, 
cells were pre-treated with etifoxine (500nM to 5000nM) (10mM stock prepared in 
DMSO and stored at -20°C)) for a total of 1 hour. The dose of etifoxine was cell type 
dependent, mouse-derived cells were pre-treated with 0.5μM – 5μM etifoxine and 
human-derived cells were pre-treated with 5μM – 50μM etifoxine. After 1 hour of 
etifoxine pre-treatment, LPS (100ng/mL) was pipetted directly into the wells. The 
cells were primed with LPS for 3 hours and then activated with nigericin (10µM) for 1 
hour. Following activation, the supernatants were collected in 1.5mL Eppendorf 
tubes, and stored at -80°C. The adherent cells that remained were either lysed with 
standard radioimmunoprecipitation assay (RIPA) buffer with 1mM Na3VO4 and BD 
Baculogold protease inhibitors (BD Biosciences) or 500μL of QIAzolⓇ reagent 
(Qiagen). Samples were then transferred to 1.5mL Eppendorf tubes and stored at -
80°C. 
Inflammasome activation and etifoxine treatment were also conducted in HITMS 
patient-derived whole-PBMCs. All patients were diagnosed with secondary 
progressive MS and were not presently using any disease modifying therapies 
(DMTs). Only patient samples that exhibited a positive response following 
inflammasome activation (IL-1β response measured via ELISA) were included. 
Patient demographics are outlined in Table 6 (Section 3.13).  
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Prior to thawing PBMCs, culture media (RPMI, P/S, 1x GlutaMAX) was warmed 
to 37°C. PBMCs were thawed by immersing cryovials into a 37°C water bath, 
however vials were not fully immersed to ensure that water did not seep through the 
cap and contaminate the sample. Once the PBMCs were mostly thawed (small ice 
crystals present in cryovial), the 1.0mL cell suspension was transferred to a 15mL 
conical. 9.0mL of pre-warmed media was then added to the 15mL conical containing 
the PBMC cell suspension. Samples were centrifuged at 300 x g for 10 minutes to 
obtain a cell pellet. The supernatant was carefully poured off and the cells were 
resuspended in 1mL of pre-warmed media, an aliquot was taken and diluted at 1:2 in 
Trypan Blue to determine the number of viable cells. Cells were then resuspended at 
5x105 cells/mL with pre-warmed media in 5mL polypropylene round-bottom tubes. 
After 1-2 days the samples were centrifuged at 300 x g for 10 minutes and 
resuspended in serum-free media. Cell suspensions were then pre-treated with 
etifoxine (50μM) and inflammasome activated according to the protocol outlined 
above. Following the inflammasome activation protocol the cell suspensions were 
transferred to 1.5mL Eppendorf tubes and micro-centrifuged at 300 x g for 10 
minutes. The supernatants were aliquoted into new 1.5mL Eppendorf tubes and 
stored at -80 °C and the cell pellets were flash frozen in liquid nitrogen and stored at 
-80 °C. 
 
2.9 Picrotoxin Treatment 
BMDMs and THP-1 macrophages were plated in 24-well plates and pre-treated 
with 50μM picrotoxin alone or with 5μM – 10μM etifoxine. Following the 30-minute 
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pre-treatment (no wash out), the cells underwent inflammasome activation in 
accordance with the protocol described above (2.8). Supernatants were collected, 
transferred to 1.5mL Eppendorf tubes, and stored at -80°C. All work was done by Dr. 
Craig Moore. 
 
2.10 RNA Isolation, Reverse Transcription, and Quantitative Polymerase 
Chain Reaction (RT-qPCR) 
The RNeasy Micro Kit (Qiagen) was used to extract RNA from cells that were 
lysed with QIAzolⓇ reagent (Qiagen). The extraction was conducted according to the 
manufacturer’s protocol. The concentration of RNA was determined by using a 
Nanodrop 1000 Spectrophotometer (Fisher Scientific). Reverse transcription was 
performed by using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer’s protocol. Polymerase chain reaction 
(PCR) was conducted with the TaqmanⓇ Fast Universal PCR Master Mix (Applied 
Biosystems). The TaqManⓇ probes and primers that were used are as follows: mIL-
1β, hIL-1β, mNLRP3, hNLRP3, mCaspase-1, 18S Endogenous Control, and 
hGAPDH Control (Applied Biosystems). RT-qPCR was performed using an Applied 
Biosystems® ViiA 7 Real-Time PCR System and analysis was conducted on 
QuantStudioTM Software by Applied Biosystems. Minus reverse transcriptase and 
no-template cDNA controls were included. Fold changes were calculated using the 2
-
ΔΔCT method (Livak and Schmittgen 2001; Schmittgen and Livak 2008). 
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2.11 RNA Sequencing 
RNA extraction was conducted according to the procedure stated above in 
section 2.9 and shipped to Imperial College, London, UK for sequencing. RNASeq 
was performed on RNA derived from microglia and monocytes isolated from EAE 
mice that were treated with either etifoxine (50mg/kg) or vehicle. Data was analysed 
using R statistical analyses software and genes were included in the analysis if they 
possessed an expression value of Log2 FPKM >0 in at least 5% of the samples 
across treatments and controls. The Bioconductor package EdgeR was used to 
perform the differential gene expression analysis, which utilized a generalized linear 
model based on a negative binomial test model for RNA-Seq in R. A cut-off of FDR 
≤0.05 (False Discovery Rate) was applied to select differentially expressed genes 
(DEGs). GeneOntology datasets on the WebGestalt webserver 
(http://www.webgestalt.org) were used to perform functional over-representation 
analyses. All work was conducted by Dr. Craig Moore (Memorial University of 
Newfoundland) and Dr. Prashant Kumar Srivastava (Imperial College of London). 
 
2.12 RT2 Profiler PCR Array 
RNA extraction and quantification were conducted according to the procedure(s) 
stated above in section 2.10.  Reverse transcription was performed by using the RT2 
First Strand Kit (Qiagen) according to the manufacturers protocol. PCR was 
conducted with the Mouse Inflammasomes (96-well format) RT2 Profiler PCR Array 
(Cat. # PAMM-097Z, Qiagen) according to the manufacturers protocol and was read 
on an Applied Biosystems® ViiA 7 Real-Time PCR System and analysis was 
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conducted on QuantstudioTM Software by Applied Biosystems. The layout of the PCR 
array 96-well plate consisted of probes/primers for 84 inflammasome-associated 
genes, 5 housekeeping controls, 1 mouse genomic DNA contamination control, 3 
reverse transcription controls, and 3 positive PCR controls. CT values for each 96-
well plate were exported to a Microsoft ExcelⓇ spreadsheet, which was then 
uploaded to the Qiagen GeneGlobe Data Analysis Center online-based software for 
further analyses, with instructions provided in the manufacturers protocol.  
Genes were considered to be up or downregulated when the fold change was 
greater than 2, which is represented by the blue lines on the scatterplots. The fold 
change cut off could be changed, however the default option was set at 2. Genes 
were considered to be unchanged (black) when they were below the fold change cut 
off value. 
 
2.13 Enzyme-Linked Immunosorbent Assay  
Human IL-1β, tumor necrosis factor (TNF), IL-6, and mouse TNF OptEIA 
enzyme-linked immunosorbent assay (ELISA) kits were used from BD Biosciences. 
Human IL-18 and mouse IL-1β ELISA kits were used from R&D Systems 
(biotechne). All ELISAs were performed according to the manufacturer’s instructions. 
Absorbance readings were obtained by using a Cytation™ 5 Cell Imaging Multi-
Mode Reader (BioTek) and concentrations were determined based on a standard 
curve with a linear line of best fit. 
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2.14 Western Blotting  
Human macrophages were inflammasome-activated according to the protocol in 
section 2.8. Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer and 
stored at -80°C. Prior to SDS-PAGE, protein lysates were thawed and diluted at a 
1:1 ratio in 2X sample buffer and heated to 95°C for 5 minutes. Samples were 
separated on WedgeWell™ 4–15% Tris-Glycine Gels (Invitrogen, Burlington, 
Canada) and transferred to 0.45 pore Immobilon- P PVDF membranes (Millipore) for 
1 hr at 100 V. Membranes were blocked overnight at 4°C in 5% skim milk in 1x tris-
buffered saline and tween 20 (TBST). Membranes were then probed with antibodies 
specific to NLRP3 (1:1000) or β-actin (1:1000) followed by HRP-linked anti-IgG 
(1:2000). Membranes were then soaked in ECL™ Western Blotting Detection Agents 
and developed. Protein loading was normalized relative to β-actin. All work was 
conducted by Dr. Craig Moore. 
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2.15 Propidium Iodide Uptake and Cytotoxicity Assay   
Propidium iodide (ThermoFisher/Life Technologies) is a cell impermeable DNA 
stain that was used to mark cells that were undergoing inflammasome-mediated cell 
death (pyroptosis). The assays were conducted in 96-well plates, in which cultured 
BMDMs and MDMs were supplemented with 100µL/well serum-free and phenol-red 
free DMEM or RPMI. One column of the 96-well plate did not contain cells, so it was 
used to account for the background fluorescence. The background fluorescence 
reading for each row was subtracted from the corresponding wells that contained 
Triton X-100 (Sigma Aldrich) and the sample being measured; this was done to 
normalize the fluorescence index throughout the experimental reading.  
For the propidium iodide uptake assay, inflammasome activation and etifoxine 
treatments were conducted according to the procedure in section 2.7, up until the 
addition of nigericin. Prior to activating cells with nigericin, the serum-free media was 
replaced with serum-free and phenol-red free media that contained 1μg/mL of 
propidium iodide. At this point there were three different tubes containing media with 
propidium iodide: a no treatment condition, a nigericin (10μM) condition, and a Triton 
X-100 (10µL/mL) condition. The 96-well plate was then transferred to the Cytation™ 
5 Cell Imaging Multi-Mode Reader (BioTek), which was set at 37°C +/- 2°C with 5% 
CO2. The fluorescence intensity was read at 533/617 (excitation/emission) every 2 
minutes for 1.5 hours. The relative propidium iodide uptake was determined with the 
following equation: 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒	𝑃𝐼	𝑈𝑝𝑡𝑎𝑘𝑒 = !"#$%&'(")*+,-./0
1,23-/	5'(")*+,-./0
 .  
For the cytotoxicity assay, the cells were only treated with various doses of 
etifoxine, which were all diluted in serum-free and phenol-red free media that 
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contained 1μg/mL of propidium iodide. In BMDMs, the conditions included:  no 
treatment, etifoxine (1μM, 3μM, 5μM, 10μM, 15μM, 30μM, 100μM, and 300μM), and 
Triton X-100. In MDMs the conditions were no treatment, etifoxine (1μM, 3μM, 10μM, 
30μM, 100μM, and 300μM), and Triton X-100. The 96-well plate was then transferred 
to the Cytation™ 5 Cell Imaging Multi-Mode Reader, which was set at 37°C +/- 2°C 
with 5% CO2. The fluorescence intensity was read at 533/617 (excitation/emission) 
every 5 minutes for 12 hours. Instead of measuring propidium iodide uptake, the 
results were displayed as mean fluorescent units to better observe if there was a 
cytotoxic effect in any of the etifoxine conditions. 
 
2.16 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Version 8.4.0. Data is 
presented in the form of the mean +/- standard error of the mean (SEM). Ordinary 
and repeated measures one-way analyses of variance (ANOVA) were conducted 
and the recommended post hoc tests that were used are mentioned in the 
corresponding figure descriptions. p<0.05 was considered significant.  
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Chapter 3:  Results 
3.1 Treatment with, etifoxine, but not XBD173, decreases clinical severity in 
EAE  
After presenting with the first clinical signs of EAE (limp/flaccid tail: approximate 
days 9-12) mice were administered either XBD173, etifoxine, or vehicle to determine 
if these pre-established TSPO ligands were capable of decreasing clinical severity. 
Mice treated with etifoxine presented with less severe clinical symptoms compared to 
the vehicle and XBD173 treatment groups. The etifoxine-treated group (Figure 2D) 
peaked at a mean score of 1.75 on day 6, which dropped to a mean score of 1.25 on 
day 8. In comparison, the vehicle (Figure 2B) and XBD173 (Figure 2C) groups 
peaked at a mean score of 2.75 and 2.66 on days 7 and 6, respectively. To further 
elucidate the mechanism of action for etifoxine in the context of altering myeloid cell 
biology, RNA was isolated from purified CD14+ monocytes (blood) and CD11b+ cells 
(brain and spinal cord tissue) to perform RNASeq. The results of the RNASeq 
strongly implicated a significant involvement of genes associated with the immune 





Figure 2: Etifoxine reversed clinical signs of EAE after 7 days of administration  
 
(A) In EAE mice, vehicle, XBD173, or etifoxine treatment was initiated 24 hours after 
the first clinical signs were observed and continued for 7 days. (B) Clinical score for 
the vehicle treatment group (n=6) peaked at a mean score of 2.75 on day 7. (C) 
Clinical score for the XBD173 treatment group (n=6) peaked at mean score of 2.66 
on day 6. (D) Clinical score for the etifoxine treatment group (n=6) peaked at a mean 
score of 1.75 on day 6 and dropped to a mean score of 1.25 on day 8. (E) Clinical 
score of each treatment group plotted together. Repeated Measures one-way 
analysis of variance was used to determine group differences between vehicle and 
XBD173 (p=0.53), vehicle and etifoxine *(p<0.05), and etifoxine and XBD173 











































































































Table 1: Pathway analysis of RNASeq performed on microglia derived from 
EAE mice that were treated with etifoxine compared to EAE mice that were 
treated with vehicle (FDR-False Discovery Rate) 
Description p-value FDR GeneSet 
Response to lipopolysaccharide 1.08 E-10 5.72 E-07 GO:0032496 
Defense response 3.23 E-09 3.85 E-06 GO:0006952 
Response to external stimulus 1.65 E-08 1.25 E-05 GO:0009605 
Immune system process 2.05 E-06 0.000633569 GO:0002376 
Cytokine production 1.16 E-05 0.002693926 GO:0001816 
Innate immune response 4.87 E-05 0.008452642 GO:0045087 




3.2 In vitro, etifoxine pre-treatment decreases IL-1β secretion in mouse-derived 
primary macrophages and microglia under inflammasome-activating 
conditions 
To further elaborate on the mechanism by which etifoxine may be inhibiting the 
inflammatory response in EAE mice, primary macrophages (Figure 3A) and microglia 
(Figure 3B) were cultured and treated with LPS and nigericin to activate the NLRP3 
inflammasome, which has recently been suggested to be involved in driving the  
pathogenesis of MS. In the absence of inflammasome activation, etifoxine (5μM) 
alone did not have an effect on IL-1β secretion; 5μM dose was pre-determined based 
on literature involving cell culture work done in microglia and astrocytes (Lee et al., 
2016), as well as preliminary results (not shown). A significant decrease in IL-1β 
expression (p<0.001) was observed in the etifoxine (5μM) pre-treatment group in 
macrophages (183.1pg/mL±89.44) and microglia (0pg/mL) when compared to 




Figure 3: IL-1β secretion is significantly decreased in primary mouse 
macrophages and microglia when pre-treated with etifoxine (5μM) under 
inflammasome-activating conditions  
 
IL-1β ELISAs were used to measure cytokine expression in supernatants of primary 
mouse macrophages (n=7) and microglia (n=8) that were either untreated, treated 
with etifoxine (5μM) (eti(5μM)), inflammasome activated (inflam), or pre- treated with 
etifoxine (5μM) under inflammasome-activating conditions (inflam + eti(5μM)). (A) IL-
1β secretion in primary mouse macrophages was decreased when treated with 
etifoxine under inflammasome-activating conditions (183.1pg/mL±89.44) compared 
to the inflammasome-only control (1426pg/mL±289.3). (B) IL-1β secretion in primary 
mouse microglia was decreased when treated with etifoxine under inflammasome-
activating conditions (0pg/mL) compared to the inflammasome-only control 
(1874pg/mL±362.2). Results are displayed as mean ± SEM. One-way analysis of 











































3.3 Etifoxine has a dose-dependent inhibitory effect on IL-1β secretion in 
human-derived primary macrophages and fetal microglia under 
inflammasome-activating conditions 
To determine if the inhibitory effects of etifoxine were also translatable to 
humans, primary human macrophages and fetal microglia were isolated and 
activated in culture. A range of doses of etifoxine (0.1-50μM) were used in 
macrophages to determine an optimal dose. In macrophages (Figure 4A) there was 
a dose-dependent effect observed, however, at lower doses (0.1μM, 1μM, and 5μM), 
etifoxine did not inhibit IL-1β compared to the inflammasome-only control. A 
significant decrease in IL-1β secretion was observed in the 25μM and 50μM pre-
treatment conditions. In microglia (Figure 4B) there was a decrease in IL-1β 
secretion in the etifoxine (50μM) (59.08pg/mL±59.08) condition when compared to 
the inflammasome-only control, but did not reach statistical significance.  
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Figure 4: IL-1β secretion is significantly decreased in primary human 
macrophages and fetal microglia when pre-treated with etifoxine under 
inflammasome-activating conditions 
 
IL-1β ELISAs were conducted on primary human macrophages (n=1-9; n=9 for No/T, 
inflammasome only, inflammasome + etifoxine (5μM), and inflammasome + etifoxine 
(50μM); n=3 for inflammasome + etifoxine (0.1μM), inflammasome + etifoxine (1μM) 
and inflammasome + etifoxine (25μM); n=1 for inflammasome + etifoxine (10μM)) 
and fetal microglia (n=3). Macrophages were untreated, inflammasome activated 
(inflam), and pre-treated with etifoxine (0.1-50μM) (eti) under inflammasome-
activating conditions. Microglia were untreated, inflammasome activated, and pre-
treated with etifoxine (5-50μM) under inflammasome-activating conditions. (A) IL-1β 
secretion in macrophages was unchanged when pre-treated with 0.1μM 
(1236pg/mL±278), 1μM (1258pg/mL±306.3), and 5μM (1286pg/mL±143.1) etifoxine 
under inflammasome-activating conditions. IL-1β secretion was significantly 
decreased when pre-treated with 25μM and 50μM etifoxine under inflammasome-
activating conditions when compared to inflammasome-only control 
(1424pg/mL±133.2). (B) IL-1β secretion in microglia was unchanged when pre-
treated with etifoxine (5μM) (1372pg/mL±906.9) and decreased when pre-treated 
with etifoxine (50μM) (59.08pg/mL±59.08) under inflammasome-activating conditions 
when compared to inflammasome-only control (1866pg/mL±681.4). Results are 
displayed as mean ± SEM. One-way analysis of variance with Tukey’s post hoc test 

















































3.4 Etifoxine inhibits IL-1β secretion both when added prior to and during the 
LPS priming step of inflammasome activation 
Since inflammasome activation in vitro generally occurs in 2 steps (LPS priming 
and nigericin execution to stimulate potassium efflux), we sought to determine a 
more defined mechanism of action and when etifoxine may be exerting its anti-
inflammatory effect during this activation protocol. To determine when etifoxine may 
be having its greatest anti-inflammatory effect, cells were either treated with etifoxine 
30 minutes prior to LPS priming, during LPS priming, or during inflammasome 
execution with nigericin. The greatest decrease in IL-1β secretion occurred in the 
etifoxine (5μM) pre-treatment group (57.21pg/mL±18.03) and the simultaneous 





Figure 5: IL-1β secretion is decreased in primary mouse BMDMs that are either 
pre-treated with etifoxine (5μM) or when simultaneously treated with LPS  
 
IL-1β secretion measured by ELISA in primary mouse macrophages (n=2) that were 
untreated, inflammasome activated (inflam) (2538pg/mL±44.08), and pre-treated with 
etifoxine (1μM, 5μM) (eti) prior to inflammasome activation (2305pg/mL±71.27, 
57.21pg/mL±18.03), with LPS (1708pg/mL±62.49, 637pg/mL±60.52), or with 
nigericin (2450pg/mL±92.58, 3052pg/mL±702). Results are displayed as mean ± 
SEM. One-way analysis of variance with Tukey’s post hoc test was used to 







































3.5 Under inflammasome-activating conditions, etifoxine decreases TNF 
release in human macrophages  
To determine whether etifoxine was exerting its anti-inflammasome effects at 
either the priming and/or executing step of the inflammasome activation paradigm, 
TNF levels were measured in the supernatants. In the priming step (LPS activation), 
if levels of TNF were lower with etifoxine pre-treatment, it would suggest that 
etifoxine is inhibiting the LPS-TLR4 mediated signaling cascade, hence ultimately 
leading to less inflammasome activation once treated with the executing nigericin 
step. Indeed, this is what was observed. Under inflammasome-activating conditions, 
TNF secretion was significantly decreased (p<0.05, p<0.01) in human macrophages 
in a dose-dependent manner when pre-treated with etifoxine (914pg/ml±323.2, 
123.2pg/ml±123.2). Furthermore, in murine macrophages (Figure 6) simultaneous 
treatment with etifoxine and nigericin did not affect inflammasome execution. This 
suggest that etifoxine has an inhibitory effect on the LPS-driven TLR4 downstream 
pathways, which may in turn modulate NF-κB activity, rather than inhibiting 
potassium-influx, which serves as the executing/activating step of inflammasome 




Figure 6: TNF secretion is decreased when primary human macrophages are 
pre-treated with etifoxine under inflammasome-activating conditions 
 
A TNF ELISA was conducted on primary human macrophages (n=3) that were 
untreated, treated with LPS, inflammasome activated (inflam), and pre-treated with 
etifoxine (5,25,50μM) (eti) under inflammasome-activating conditions. IL-1β secretion 
significantly decreased in a dose-dependent manner when pre-treated with etifoxine 
(25μM,50μM) under inflammasome-activating conditions (914pg/ml±323.2, 
123.2pg/ml±123.2) compared to the inflammasome-only control. Results are 
displayed as mean ± SEM. One-way analysis of variance with Tukey’s post hoc test 


























3.6 Etifoxine pre-treatment results in the downregulation of inflammasome-
associated genes in primary mouse-derived macrophages and microglia 
RT-qPCR was conducted to determine if etifoxine pre-treatment in murine 
myeloid cells altered the expression of inflammasome-related genes, including il-1β 
and nlrp3. In macrophages, there was a 180-fold decrease in il-1β expression 
(Figure 7A) and a 112-fold decrease in nlrp3 expression (Figure 7C) when compared 
to inflammasome-only controls. In microglia there was a 1125-fold decrease in il-1β 
expression (Figure 7B) and a 48-fold decrease in nlrp3 expression (Figure 7D) when 




Figure 7: Inflammasome-associated gene expression is decreased in primary 
mouse macrophages and microglia following pre-treatment with etifoxine 
(5μM) under inflammasome-activating conditions 
 
 RT-qPCR was performed using RNA isolated from primary mouse macrophages 
and microglia (n=4) that were untreated, treated with etifoxine (5μM) (eti), 
inflammasome activated (inflam), or pre-treated with etifoxine (5μM) under 
inflammasome-activating conditions. (A) Fold change of il-1β mRNA in macrophages 
was significantly decreased when pre-treated with etifoxine under inflammasome-
activating conditions (73.52±8.71) compared to the inflammasome-only control 
(252.7±62.86). (B) Fold change of il-1β mRNA in microglia was significantly 
decreased when pre-treated with etifoxine under inflammasome-activating conditions 
(22.21±14.87) compared to the inflammasome-only control (1148±357.4). (C) Fold 
change of nlrp3 mRNA in macrophages was significantly decreased when pre-
treated with etifoxine under inflammasome-activating conditions (10.13±0.63) 
compared to the inflammasome-only control (122.3±41.51). (D) Fold change of nlrp3 
mRNA in microglia was significantly decreased when pre-treated with etifoxine under 
inflammasome-activating conditions (4.86±1.68) compared to the inflammasome-only 
control (53.22±10.75). All fold changes were calculated by using the 2-ΔΔCT method. 
Results are displayed as mean ± SEM. One-way analysis of variance with Tukey’s 

































































































3.7 Pre-treatment with etifoxine decreases inflammasome-associated gene and 
protein expression in activated human-derived primary macrophages 
RT-qPCR was performed to determine if etifoxine exerted a similar effect on 
inflammasome-related gene expression in human as previously shown in murine 
cells. There was a 128-fold decrease in il-1β (Figure 8A), 1.5-fold decrease in nlrp3 
(Figure 8B), and 28-fold decrease in tnf⍺-ip3 (Figure 8C) expression when pre-
treated with etifoxine (50μM) under inflammasome-activating conditions compared to 
the inflammasome-only controls. Western blotting for NLRP3 protein confirmed a 









Figure 8: Inflammasome-associated gene expression is decreased when 
primary human macrophages are pre-treated with 50μM etifoxine under 
inflammatory conditions 
 
RT-qPCR was performed on primary human macrophages (n=4) that were 
untreated, inflammasome-activated (inflam), and pre-treated with etifoxine (50μM) 
(eti) under inflammasome-activating conditions. Western blotting for NLRP3 was also 
performed on primary human macrophages that were untreated, inflammasome-
activated (inflam), and pre-treated with etifoxine (50μM) (eti) under inflammasome-
activating conditions. Protein loading was normalized to relative β-actin. Fold change 
of il-1β mRNA when pre-treated with etifoxine (50μM) under inflammasome-
activating conditions (7.21±2.75) compared to the inflammasome-only control 
(135.4±12.62). (B) Fold change of nlrp3 mRNA when pre-treated with etifoxine (5μM, 
50μM) under inflammasome-activating conditions (0.43±0.07) compared to the 
inflammasome-only control (1.65±0.10). (C) Fold change of tnf⍺-ip3 mRNA when 
pre-treated with etifoxine (50μM) under inflammasome-activating conditions 
(2.40±0.39) compared to the inflammasome-only control (30.38±6.01). (D) Pre-
treatment with etifoxine (50μM) decreased NLRP3 protein expression under 
inflammasome-activating conditions when compared to the inflammasome-only 
control. All fold changes were calculated by using the 2-ΔΔCT method. Results are 
displayed as mean ± SEM. One-way analysis of variance with Tukey’s post hoc test 

























































































3.8 Etifoxine does not have a cytotoxic effect in naïve mouse-derived and 
human-derived primary macrophages 
A wide dose (1-300μM) cytotoxicity assay was conducted in naïve murine- and 
human-derived primary macrophages to determine if high concentrations of etifoxine 
were implementing a cytotoxic effect. In both human and murine macrophages, 
etifoxine did not increase the PI fluorescent signal when measured over a 5-hour 
time period, regardless of concentration. Treatment with Triton X served as the 
positive control and quickly resulted in a positive PI signal that peaked at 
approximately 2700 RFU followed by a plateau in mice; approximately 2600 RFU in 
human cells. The PI signal in the etifoxine conditions did not exceed 900 RFU in both 
mice and humans. In humans, (Figure 9B) there was an initial increase in 
fluorescence in the Triton X condition, which later decreased; this could be the result 
of cells becoming non-adherent in the wells. Small increases in cell death were 
observed at higher concentrations of etifoxine, likely due to cytotoxic effects of 




Figure 9: In human and mouse macrophages, etifoxine is not cytotoxic at 
doses that block IL-1β secretion 
 
 Cytotoxicity assays were conducted in mouse and human primary macrophages 
(n=2) and all treatments occurred in the absence of inflammasome-activating 
conditions. The assays were conducted in real-time using the CytationTM 5 Cell 
Imaging Multi-Mode Reader for 5 hours. (A) Primary mouse macrophages were 
untreated, treated with etifoxine (1μM-300μM) (eti), and treated with Triton X. The 
Triton X condition peaked and plateaued at approximately 2700 RFU, the etifoxine 
(100μM, 300μM) conditions peaked at 800 RFU, and the lower doses (1μM-30μM) 
were consistent with the untreated control. (B) Human macrophages were untreated, 
treated with etifoxine (1μM-300μM), and treated with Triton X. The Triton X condition 
peaked at approximately 2600 RFU and steadily decreased to 1500 RFU, the 
etifoxine (30μM-300μM) conditions peaked at 650 RFU, and the lower doses (1μM-
10μM) were consistent with the untreated control. 
 
 






























































3.9 Etifoxine does not influence cell viability in human-derived primary 
macrophages under inflammasome-activating conditions, but not in mouse-
derived primary macrophages 
This assay was conducted to ensure that etifoxine was not initiating any form of 
cell death prior to the cells undergoing pyroptosis. Etifoxine alone did not affect cell 
viability (Figure 9), so we wanted to determine if etifoxine treatment under 
inflammasome-activating conditions could rescue macrophages from undergoing 
pyroptosis. In murine macrophages, pre-treatment with etifoxine did not have an 
effect on PI uptake under inflammasome-activating conditions, this observation was 
present in both the untreated (mean difference of 0.03 or 3%) and inflammasome-
only controls (mean difference of 0.03 or 3%). In human macrophages, PI uptake 
was decreased when pre-treated with etifoxine (50μM) under inflammasome-
activating conditions in comparison to the inflammasome-only control (mean 
difference of 0.31 or 31%), and unchanged when compared to the untreated control 
(mean difference of 0.08 or 8%). This provided validation that etifoxine was not 




Figure 10: Propidium iodide uptake is unchanged in primary mouse 
macrophages when pre-treated with etifoxine (5μM), and decreased in primary 
human macrophages when pre-treated with etifoxine (50μM) under 
inflammasome-activating conditions 
 
Propidium iodide uptake assays were conducted in primary mouse macrophages 
(n=1) and primary human macrophages (n=2). The assays were conducted in real-
time using the CytationTM 5 Cell Imaging Multi-Mode Reader for 1-1.5 hours. (A) 
Primary mouse macrophages were untreated, treated with etifoxine (5μM) (eti), 
inflammasome activated (inflam), and pre-treated with etifoxine (5μM) under 
inflammasome-activating conditions. PI uptake in macrophages that were pre-treated 
with etifoxine under inflammasome-activating conditions did not differ from the 
inflammasome-only control, there was also no difference between the etifoxine 
condition and the untreated control. (B) Primary human macrophages were 
untreated, treated with etifoxine (50μM), inflammasome activated, and pre-treated 
etifoxine (5μM,50μM) under inflammasome activating conditions. PI uptake was 
reduced when macrophages were pre-treated with etifoxine (50μM) under 
inflammasome-activating conditions compared to the inflammasome-only control and 
did not differ compared to the untreated control. PI uptake was calculated using the 
following equation: 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝑃𝐼𝑈𝑝𝑡𝑎𝑘𝑒 = !"#$%&'(")*+,-./0
1,23-/	5'(")*+,-./0
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3.10 Pharmacological inhibition of GABAA receptors in murine macrophages 
and human THP-1 cells does not negatively impact the ability of etifoxine to 
inhibit the inflammasome 
GABAA receptors have been previously described as a binding partner of 
etifoxine and myeloid cells have been shown to express these receptors (Bhandage 
et al., 2019; Mattei et al., 2019a). In regard to inflammation, prior findings have 
indicated that GABAA receptors are capable of modulating inflammation, however the 
anti-inflammatory effect is highly dependent on the pharmaceutical agonist being 
used (Crowley et al., 2016). In order to elucidate whether etifoxine might be working 
via a GABAA-mediated mechanism to inhibit inflammasome activation, picrotoxin, the 
prototypic GABAA antagonist was used to block GABAA receptors. In primary mouse 
macrophages (Figure 11A), pre-treatment with picrotoxin alone did not affect IL-1β 
secretion under inflammasome-activating conditions. In further investigation using 
THP-1 macrophages (Figure 11B), picrotoxin alone did not influence IL-1β secretion 
(data not shown).  When comparing the etifoxine-treated (5μM-10μM) inflammasome 
condition (1149pg/mL±52.27, 1269pg/mL±15.97) with the etifoxine and 
picrotoxin0treated inflammasome condition levels were decreased. Due to the 
inability of picrotoxin to block the anti-inflammasome activating condition, it is 
concluded that the ability of etifoxine to inhibit the inflammasome is not via the 




Figure 11: IL-1β secretion is unchanged when primary mouse BMDMs and 
human THP-1 macrophages are pre-treated with picrotoxin 
 
IL-1β ELISAs were conducted in primary mouse macrophages (n=3) and human 
THP-1 macrophages (n=6). (A) Primary mouse macrophages were untreated, 
inflammasome activated (inflam), and pre-treated with either picrotoxin (50μM) or 
DMSO under inflammasome-activating conditions. IL-1β secretion did not differ when 
comparing the pre-treatment with picrotoxin under inflammasome-activating 
conditions (200pg/mL±85.91) to the inflammasome-only control (198pg/mL±60.89). 
(B) THP-1 macrophages were untreated, treated with picrotoxin (50μM), 
inflammasome activated, and pre-treated with either DMSO, etifoxine alone (5μM, 
10μM) (eti), or picrotoxin (50μM) and etifoxine (5μM, 10μM) under inflammasome-
activating conditions. Picrotoxin alone did not affect IL-1β secretion when compared 
to the untreated control. IL-1β secretion was decreased when pre-treated with 
etifoxine (5μM, 10μM) alone (1621pg/mL±38.15, 1602pg/mL±130.28) and with the 
addition of picrotoxin (1149pg/mL±52.27, 1269pg/mL±15.97) under inflammasome-
activating conditions compared to the inflammasome-only control. Results are 
displayed as mean ± SEM. One-way analysis of variance with Tukey’s post hoc test 














































3.11 Pre-treatment with etifoxine significantly alters inflammasome-
associated gene expression in primary mouse macrophages 
To further explore additional genes and/or inflammasome-related pathways that 
may be altered as a result of etifoxine pre-treatment in primary mouse macrophages 
(other than NLRP3), a Qiagen RT2 qPCR array containing 86 inflammasome-specific 
genes was performed. The conditions compared were inflammasome only vs. no 
treatment (Table 2, Figure 12), etifoxine (5μM) under inflammasome activating 
conditions vs. no treatment (Table 3, Figure 13), and etifoxine (5μM) under 
inflammasome activating conditions vs. inflammasome only (Table 4, Figure 14). A 
biological n=3 was used and the averages were calculated to determine which genes 
were upregulated (green) and/or downregulated (red).  
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Table 2: Gene Regulation in inflammasome activated primary mouse 
macrophages when compared to untreated control. Upregulated genes (>2-fold 
change) are colored in green and unchanged genes (<2-fold change) are 
colored in black 
Gene Regulation Gene Regulation 
Il1β 25.34 Fadd 2.47 
Ccl5 13.21 Mapk13 2.46 
Cxcl1 12.37 Casp1 2.44 
Cxcl3 10.91 Tab1 2.39 
Tnf 8.44 Tnfsf14 2.38 
Il6 8.31 Tab2 2.31 
Nlrp3 6.9 Rela 2.26 
Il12b 6.06 Ccl7 2.23 
Irf4 6 Mapk3 2.18 
Ifnβ1 5.19 Nfkb1 2.18 
Ptgs2 5.1 Irak1 2.16 
Bcl2 5.09 Nfkbib 2.1 
Nlrx1 4.84 Pycard 2.08 
Ccl12 4.31 P2rx7 1.98 
Tnfsf4 4.31 Nfkbia 1.95 
Ciita 4.03 Nlrc5 1.87 
Irf1 3.78 Aim2 1.82 
Myd88 3.68 Mapk12 1.76 
Nlrp1a 3.61 Nod2 1.75 
Ifng 3.53 Mok 1.74 
Il12a 3.53 Irf3 1.71 
Naip1 3.53 Mapk11 1.63 
Nlrp5 3.53 Hsp90b1 1.59 
Nlrp6 3.53 Txnip 1.51 
Nlrp9b 3.53 Xiap 1.47 
Birc3 3.52 Nlrc4 1.43 
Card6 3.47 Sugt1 1.34 
Nlrp4e 3.4 Ctsb 1.33 
Cd40lg 3.37 Ikbkb 1.2 
Ripk2 3.37 Mapk8 1.18 
Bcl2l1 3.27 Map3k7 1.15 
Cflar 3.14 Birc2 1.13 
Pstpip1 2.99 Hsp90aa1 1.12 
Nlrp4b 2.95 Il18 1.03 
Nlrp12 2.92 Il33 1.02 
Naip5 2.91 Mapk1 0.95 
Traf6 2.72 Pea15a 0.92 
Mefv 2.64 Tirap 0.88 
Nod1 2.62 Panx1 0.8 
Casp8 2.59 Mapk9 0.7 
Tnfsf11 2.57 Casp12 0.63 




Figure 12: Scatterplot displaying gene expression when comparing 
inflammasome-activated primary mouse macrophages to untreated control 
 
A Qiagen data analysis web-based program was used to determine the fold 
regulation by using the 2-ΔΔCT method. Initially the ΔCT is calculated between the 
genes of interest and the reference genes, which is then followed by the ΔΔCT and 
fold change calculations between the test group (inflammasome-only) and the control 
group (no treatment) (n=3). Points are plotted as log10 values. The scatterplot 
compares the normalized gene expression between the test group and the control 
group, the black line represents unchanged (<2-fold) gene expression and the blue 
lines represent the >2-fold change threshold. Upregulated genes are colored in 
green, unchanged genes are colored in black, and downregulated genes are colored 
in red. Individual points in the upper left and lower right quadrants are up- and 
downregulated by >2-fold in the inflammasome-only group compared to the control 
group. The compared groups had a biological n=3. Genes with the greatest increase 





























Table 3: Gene Regulation in primary mouse macrophages pre-treated with 
etifoxine (5μM) under inflammasome-activating conditions when compared to 
untreated control. Upregulated genes (>2-fold change) are colored in green, 
downregulated genes are colored in red, and unchanged genes (<2-fold 
change) are colored in black  
Gene Regulation Gene Regulation 
Card6 124.78 Irf4 3.37 
Bcl2 106.16 Traf6 3.25 
Ccl5 59.14 Myd88 2.98 
Aim2 53.28 Nlrc4 2.91 
Bcl2l1 43.19 Tnfsf14 2.85 
Naip1 41.97 Ciita 2.67 
Birc2 29.88 Nod2 2.59 
Birc3 29.11 Mapk12 2.58 
Il1β 28.16 Mok 2.56 
Nlrp5 24.22 Mefv 2.42 
Il12b 19.35 Irak1 2.29 
Cxcl3 18.39 Cflar 2.2 
Ccl12 17.82 Cxcl1 2.11 
Nlrp6 15.65 Mapk11 2.07 
Ifng 13.8 Pycard 2.06 
Il12a 13.11 Tnfsf11 1.94 
Nlrp1a 13.07 Irf3 1.79 
Cd40lg 12.85 Ikbkg 1.67 
Ptgs2 12.69 Nfkbib 1.65 
Ccl7 11.95 Hsp90b1 1.51 
Mapk13 9.29 Irf1 1.51 
Nlrp12 8.78 Tirap 1.5 
Casp8 7.25 Rela 1.41 
Naip5 7.18 Nlrp3 1.3 
Tnfsf4 6.48 Pea15a 1.21 
Il6 6.12 Il18 1.16 
Txnip 5.77 Casp1 0.99 
Tab2 5.74 Mapk3 0.99 
Nlrp9b 5.47 Fadd 0.82 
Nod1 5.4 Mapk8 0.77 
Pstpip1 5.37 Map3k7 0.76 
Ifnβ1 5.34 Chuk 0.75 
Tnf 4.84 Sugt1 0.72 
Nlrp4e 4.71 Nfkb1 0.71 
Casp12 4.52 Mapk9 0.6 
Nlrp4b 4.32 Ctsb 10.88 
Il33 4.11 Mapk1 6.11 
Tab1 4.03 P2rx7 4.65 
Ikbkb 3.96 Nfkbia 3.34 
Ripk2 3.85 Panx1 2.77 
Nlrx1 3.72 Hsp90aa1 2.27 
Nlrc5 3.68 Xiap 2.11 
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Figure 13: Scatterplot displaying gene expression when comparing primary 
mouse macrophages that have been pre-treated with etifoxine (5μM) under 
inflammasome-activating conditions to untreated control 
 
A Qiagen data analysis web-based program was used to determine the fold 
regulation by using the 2-ΔΔCT method. Initially the ΔCT is calculated between the 
genes of interest and the reference genes, which is then followed by the ΔΔCT and 
fold change calculations between the test group (inflammasome + etifoxine) and the 
control group (no treatment) (n=3). Points are plotted as log10 values. The scatterplot 
compares the normalized gene expression between the test group and the control 
group, the black line represents unchanged (<2-fold) gene expression and the blue 
lines represent the >2-fold change threshold. Upregulated genes are colored in 
green, unchanged genes are colored in black, and downregulated genes are colored 
in red. Individual points in the upper left and lower right quadrants are up- and 
downregulated by >2-fold in the inflammasome + etifoxine group compared to the 








































Table 4: Gene Regulation in primary mouse macrophages pre-treated with 
etifoxine (5μM) under inflammasome-activating conditions when compared to 
inflammasome-only control. Upregulated genes (>2-fold change) are colored in 
green, downregulated genes are colored in red, and unchanged genes (<2-fold 
change) are colored in black  
Gene Regulation Gene Regulation 
Card6 36 Nlrp4e 1.38 
Aim2 29.33 Pea15a 1.32 
Birc2 26.46 Mapk11 1.27 
Bcl2 20.85 Tnfsf14 1.2 
Bcl2l1 13.21 Traf6 1.2 
Naip1 11.88 Ripk2 1.14 
Birc3 8.27 Il18 1.12 
Casp12 7.23 Il1β 1.11 
Nlrp5 6.86 Irak1 1.06 
Ccl7 5.37 Irf3 1.05 
Ccl5 4.48 Pycard 0.99 
Nlrp6 4.43 Hsp90b1 0.95 
Ccl12 4.13 Mefv 0.92 
Il33 4.01 Mapk9 0.86 
Cd40lg 3.82 Nfkbib 0.78 
Txnip 3.82 Nlrx1 0.77 
Mapk13 3.77 Tnfsf11 0.76 
Il12a 3.71 Il6 0.74 
Nlrp1a 3.62 Cflar 0.7 
Ikbkb 3.31 Map3k7 0.67 
Il12b 3.19 Ciita 0.66 
Nlrp12 3.01 Mapk8 0.65 
Ikbkg 2.84 Myd88 0.65 
Casp8 2.79 Rela 0.62 
Ifng 2.66 Tnf 0.57 
Ptgs2 2.49 Irf4 0.56 
Tab2 2.48 Tab1 0.55 
Naip5 2.47 Ctsb 14.5 
Nod1 2.06 P2rx7 9.22 
Nlrc4 2.03 Nfkbia 6.5 
Nlrc5 1.97 Cxcl1 5.85 
Pstpip1 1.8 Mapk1 5.82 
Tirap 1.7 Nlrp3 5.3 
Cxcl3 1.69 Chuk 3.39 
Nlrp9b 1.55 Xiap 3.1 
Ifnβ1 1.51 Nfkb1 3.07 
Tnfsf4 1.5 Fadd 3.02 
Nod2 1.48 Hsp90aa1 2.54 
Mapk12 1.47 Irf1 2.5 
Mok 1.47 Casp1 2.46 
Nlrp4b 1.47 Panx1 2.23 
Sugt1 1.47 Mapk3 2.19 
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Figure 14: Scatterplot displaying gene expression when comparing primary 
mouse macrophages that have been pre-treated with etifoxine (5μM) under 
inflammasome-activating conditions to inflammasome-only control 
 
A Qiagen data analysis web-based program was used to determine the fold 
regulation by using the 2-ΔΔCT method. Initially the ΔCT is calculated between the 
genes of interest and the reference genes, which is then followed by the ΔΔCT and 
fold change calculations between the test group (inflammasome + etifoxine) and the 
control group (inflammasome only) (n=3). Points are plotted as log10 values. The 
scatterplot compares the normalized gene expression between the test group and 
the control group, the black line represents unchanged (<2-fold) gene expression 
and the blue lines represent the >2-fold change threshold. Upregulated genes are 
colored in green, unchanged genes are colored in black, and downregulated genes 
are colored in red. Individual points in the upper left and lower right quadrants are 
up- and downregulated by >2-fold in the inflammasome + etifoxine group compared 
to the inflammasome-only group. Genes with the greatest increase/decrease in fold 







































3.12 SPMS patient-derived monocytes display an increased susceptibility to 
LPS treatment when compared to healthy controls 
To further investigate the potential involvement of inflammasome activation in 
relation to the progressive nature of MS (Table 5), we sought to determine the effect 
that LPS activation had on pro-inflammatory cytokine secretion in vitro. Healthy 
control and SPMS patient-derived monocytes were treated with LPS; LPS treatment 
alone induces inflammasome activation in monocytes (Gaidt & Hornung, 2017). IL-1β 
(Figure 15A) and TNF (Figure 15B) expression were significantly increased in SPMS 
patients when compared to healthy controls; IL-6 (Figure 15C) was unchanged. This 
showed that monocytes derived from SPMS patients were more sensitive to LPS 
treatment. 
Table 5: Patient demographics for the healthy control and SPMS patient-
derived monocytes 
 Control SPMS 
Age 56±7.2 (41-63) 53.8±10.0 (43-73) 
Sex 5♀; 3♂ 5♀; 3♂ 
EDSS N/A 6.5-7.0 





Figure 15: Monocytes derived from SPMS patients display an increased 
sensitivity to LPS treatment when compared to monocytes derived from age 
and sex matched healthy controls 
 
ELISAs were conducted in monocytes derived from healthy controls (n=8/group) and 
SPMS patients (n=8/group). The control and SPMS monocytes were either untreated 
or treated with LPS. (A) ELISA comparing IL-1β secretion in monocytes from healthy 
controls and SPMS patients. IL-1β secretion was significantly increased in SPMS 
patients (2174pg/mL±204.4) when compared to healthy controls (1451pg/mL±142.3).  
(B) ELISA comparing IL-6 secretion in monocytes from healthy controls and SPMS 
patients. There was no significant difference in IL-6 secretion in SPMS patients 
(15441pg/mL±1164) compared to healthy controls (18266pg/mL±1095). (C) ELISA 
comparing TNF secretion in monocytes from healthy controls and SPMS patients. 
TNF secretion was significantly increased in SPMS patients (2055pg/mL±408.8) 
when compared to healthy controls (781.5pg/mL±254.1).  Results are displayed as 
mean ± SEM. Two-way analysis of variance with multiple comparisons between 

















































3.13 Pre-treatment with etifoxine decreases IL-1β secretion in activated 
SPMS patient-derived PBMCs 
To determine if the inhibitory effect of etifoxine was clinically relevant, PBMCs 
derived from SPMS patients (Table 6) were either untreated, inflammasome 
activated (LPS and nigericin), and pre-treated with etifoxine (50μM) under 
inflammasome activating conditions. IL-1β secretion was significantly decreased 
when PBMCs were pre-treated with etifoxine under inflammasome activating 
conditions when compared to inflammasome-only controls.  
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Table 6: Patient demographics for the SPMS-patient derived whole blood 
PBMCs that were untreated, inflammasome activated, and pre-treated with 
etifoxine (50μM) under inflammasome activating conditions 




*no DMT use   
 
 
Figure 16: Pre-treatment with etifoxine (50μM) decreases IL-1β secretion in 
SPMS patient-derived PBMCs under inflammasome activating conditions 
 
An IL-1β ELISA was conducted on PBMCs derived from SPMS patients (n=3). 
PBMCs were untreated, inflammasome activated (inflam), and pre-treated with 
etifoxine (50μM) (eti) under inflammasome activating conditions. IL-1β secretion was 
significantly decreased when pre-treated with etifoxine (50μM) under inflammasome 
activating conditions (725.6pg/mL±177.5) when compared to inflammasome-only 
control (2428pg/mL±786.7). Results are displayed as mean ± SEM. One-way 
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Chapter 4:  Discussion 
The primary objective of this thesis was to investigate the ability of etifoxine, a 
small-molecule TSPO ligand, to influence inflammasome activation in murine- and 
human-derived myeloid cells in the pathological context of MS. Previous research 
has demonstrated that etifoxine possesses an anti-inflammatory effect when utilized 
as a form of treatment in vivo. (Daugherty et al., 2013; Ravikumar et al., 2016). In the 
commonly used animal model of MS, EAE, etifoxine treatment prior to disease onset 
was associated with decreased clinical severity in both mouse (Daugherty et al., 
2013) and rat models (Ravikumar et al., 2016). These studies suggested that 
etifoxine induces a neuroprotective effect because it increased neurosteroid levels in 
EAE; however, there is contradictory evidence that suggests otherwise. For example, 
when etifoxine and XBD-173 (both TSPO ligands) were compared as forms of 
treatment for EAE, etifoxine treatment decreased both clinical severity and immune 
cell infiltration while increasing oligodendroglial regeneration (Daugherty et al., 2013; 
Ravikumar et al., 2016). In contrast, treatment with XBD-173 did not alter the EAE 
phenotype, yet did increase the concentration of neurosteroids in rodents; etifoxine 
treatment did not alter the level of neurosteroids. Taken together, these findings 
suggest a potentially novel mechansim by which etifoxine is able to influence 
neuroimmunological and pathological mechanisms that are unrelated to neurosteroid 
synthesis.  
Aside from EAE-based studies, there is evidence to support the use of etifoxine 
as a form of treatment in an animal model of traumatic brain injury (TBI) (Shehadeh 
et al., 2019; Simon-O’Brien et al., 2016). In this case, etifoxine had an ameliorative 
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effect on both the physiological and cognitive deficits that are typical of TBI. 
Following etifoxine treatment, the TBI-induced rats had reduced apoptotic acitvity 
and increased neuronal survival within cortical lesions (Shehadeh et al., 2019). In 
addition,  etifoxine treatment in TBI-induced rats also resulted in improved cognitive 
and behavioural functioning compared to a vehicle-treated group (Simon-O’Brien et 
al., 2016). In vivo, etifoxine has also been shown to have a protective effect in the 
peripheral nervous system, particularly following cryolesioning of the sciatic nerve in 
rats (Girard et al., 2008). Specifically, animals treated with etifoxine had increased 
axonal regeneration, decreased macrophage infiltration, and exhibited improved 
motor and sensory functioning.  
In the studies mentioned above, authors have concluded that the benefical 
effects of etifoxine are steroid related and mediated by its ability to modulate TSPO 
activity in the CNS and produce neurosteroids, including progesterone and 
allopregnanolone. These two neurosteroids in particular have been shown to 
contribute to the neuroprotective effects that have been observed in inflammatory 
diseases, such as MS (Daugherty et al., 2013). This proposed mechanism of action, 
however, cannot fully explain etifoxine’s potent anti-inflammatory effect in microglia 
since both rodent and human microglia do not express CYP11A1, an enzyme 
responsible for synthesizing steroids de novo (Gottfried-Blackmore et al., 2008; 
Owen et al., 2017). Despite the inability to produce steroids, the treatment of 
etifoxine in microglia still exerts an anti-inflammatory effect (Owen et al., 2017), 
whereby the mechanism is currently unknown. Due to the significant role that 
microglia play in mediating neuronal injury, it was hypothesized that the 
immunomodulatory effect and mechanism of action for etifoxine are independent of 
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TSPO and neurosteroid synthesis. To further elucidate a mechanism, preliminary 
RNASeq experiments suggested that expression levels of several genes related to 
the recognition of pathogen- and danger-associated molecular patterns (PAMPs and 
DAMPs) were significantly altered in microglia that were isolated from EAE mice 
following treatment with etifoxine (Table 1). We therefore hypothesized that a novel 
mechanism of action related to etifoxine may be related to its ability to influence 
inflammasome activation, a critical immune-mediated process that has been 
implicated in driving oligodendroglial death in MS (Loda & Balabanov, 2012; 
McKenzie et al., 2018)		
To test our hypothesis, preliminary experiments were performed in vitro using 
both primary mouse and human-derived myeloid cells, specifically brain-derived 
microglia and peripheral monocyte-derived macrophages. Initially, we also replicated 
previous in vivo data demonstrating the anti-inflammatory effects of etifoxine on the 
clinical severity and recovery in EAE. When EAE mice were treated with etifoxine 
24hrs after first clinical signs (flaccid/weak tail), we observed similar results as others 
(Barclay & Shinohara, 2017; Daugherty et al., 2013; Ravikumar et al., 2016), in 
which there was an overall decrease in clinical severity (Figure 2E). In comparison, 
XBD173, a TSPO ligand that was also tested, did not have an effect on the clinical 
severity of EAE (Figure 2C). These results support previous evidence demonstrating 
that XBD173 does not ameliorate EAE symptoms (Ravikumar et al., 2016) and 
suggests that etifoxine may have non-TSPO related mechanisms of action that 
contribute to its therapeutic potential. RNASeq results (Table 1) obtained from 
microglia isolated from EAE mice provides further validation that etifoxine may be 
mediating its therapeutic effect by inhibiting the inflammatory response. This was 
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evident by the involvement of genes associated with the immune response, innate 
immunity, cytokine production, and the defence response.  
Previous investigations have suggested a key role for the NLRP3 inflammasome 
in both the pathophysiology of MS and EAE (Barclay & Shinohara, 2017; Gris et al., 
2010; Mc Guire et al., 2013; McKenzie et al., 2018; Zheng et al., 2020). In NLRP3 
knock-out animals, the absence of NLRP3 resulted in a protective effect in EAE mice 
following induction; two additional components of the inflammasome (ASC and 
caspase-1), were also shown to play a vital role in EAE. There is also evidence 
demonstrating that inflammasome activation in EAE promotes the migration of 
inflammatory cells into the CNS (Inoue et al., 2012), thereby promoting disease 
progression and severity. An NLRP3 inhibitor, MCC950, has also been shown to 
provide further evidence for a pathogenic role that NLRP3 may play in EAE disease 
severity and progression, as well as in myeloid cells in vitro (Coll et al., 2015; Hou et 
al., 2020) . In EAE, MCC950 treatment ameliorated disease severity, conserved 
cognitive functioning throughout disease progression, and maintained neuronal 
density in the hippocampus (Coll et al., 2015; Hou et al., 2020).  Furthermore, the 
NF-kB signaling cascade that activates NLRP3 has also been implicated in both EAE 
and MS disease pathogenesis (Mc Guire et al., 2013; Voet et al., 2018; Zheng et al., 
2020). As displayed in figure 1, the TLR4/MyD88/NF-kB pathway stimulates NLRP3 
assembly and subsequent pro-inflammatory cytokine release, however this pathway 
also regulates the differentiation of Th1 and Th17 cells which are vital for the 
induction of EAE (Reynolds et al., 2010, 2012; Zheng et al., 2020). Prior research 
has shown that EAE symptoms were abolished when TLR4 was not expressed on 
CD4+ T cells, mainly because it hindered the Th17 cell responses (Reynolds et al., 
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2010, 2012). More so in regard to NLRP3, recent evidence has proposed the 
involvement of GSDMD, a pore-forming protein, in driving inflammasome-mediated 
cell death (McKenzie et al., 2018). Caspase-1 is responsible for activating GSDMD, 
and it has been shown that inhibiting caspase-1 by drug treatment in EAE resulted in 
decreased CNS inflammation, decreased expression of inflammasome-related 
genes, and maintained the density of motor neurons in the spinal cord. GSDMD was 
also found to be expressed in human microglia and oligodendrocytes under 
inflammasome-activating conditions, however, when cells were pre-treated with a 
caspase-1 inhibitor, the expression of GSDM was decreased along with the 
percentage of cells that expressed a pyroptosis-associated phenotype. Lastly, white 
matter lesions isolated from MS patient tissue had increased expression of GSDM 
compared to non-MS white matter, further suggesting that the inflammasome is a 
driving force for disease pathogenesis in MS (Barclay & Shinohara, 2017; McKenzie 
et al., 2018).  
The NLRP3 inflammasome is activated by perturbations within the cell, such as 
altered potassium efflux, pore-forming toxins, mitochondrial dysfunction, and 
lysosomal rupture (Barclay & Shinohara, 2017; Gaidt & Hornung, 2017; Groß et al., 
2016). Often, this triggers a signaling cascade to assemble the inflammasome, which 
ultimately results in the secretion of the potent pro-inflammatory molecules IL-1β and 
IL-18. IL-1β is a known contributor of MS disease progression and recent findings 
have shown that IL-1β-expressing myeloid cells are prevalent in white and gray 
matter lesions in both EAE and MS (Burm et al., 2016; Prins et al., 2013). 
Additionally, in EAE, IL-1β functions to hinder the integrity of the blood-brain and 
blood-spinal cord barriers (Argaw et al., 2006), thereby allowing immune cell 
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infiltration into the CNS. Immune cell infiltration is one of the early developments of 
driving disease progression in MS and EAE (Kermode et al., 1990; Paul & Bolton, 
1995).  
To further elucidate the inflammasome-associated mechanism of action for 
etifoxine, we investigated whether IL-1β secretion in myeloid cells was altered when 
cells were pre-treated with etifoxine under inflammasome-activating conditions. 
Etifoxine significantly decreased IL-1β release in both murine macrophages and 
microglia (Figure 3), which supports prior evidence that etifoxine possesses an anti-
inflammatory effect in murine myeloid cells (Barclay & Shinohara, 2017; Gris et al., 
2010; Owen et al., 2017). Similar results were observed using human myeloid cells 
(Figure 4). Compared to rodent cells, human-derived myeloid cells required a higher 
dose of etifoxine to decrease IL-1β secretion, which may be the result of species-
specific expression of surface Toll-like receptors and pattern recognition receptors 
involved in inflammasome activation (Lech et al., 2010). Since the inflammasome 
activation paradigm in vitro is comprised of two time-sensitive steps, (i.e. LPS 
priming and execution with nigericin (Biswas et al., 2016; Cheneval et al., 1998; Coll 
et al., 2015; Perregaux & Gabel, 1994), we sought to determine whether etifoxine 
was mediating its action at either the stage of LPS activation (priming step) and/or at 
the stage when nigericin is added (execution step). Initially, the pre-treatment of 
etifoxine occurred prior to both LPS priming and the execution with nigericin; these 
results did not provide any insight into the point at which etifoxine is inhibiting the 
inflammasome. This led us to conduct a time course-dependent assay where 
etifoxine was used as: 1) a pre-treatment, 2) in combination with LPS, or 3) in 
combination with nigericin (Figure 5). Results of these experiments confirmed that 
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etifoxine was likely exerting its anti-inflammatory effect when used as a pre-treatment 
and in combination with LPS since etifoxine had no effect on IL-1β secretion when 
used at the stage of nigericin treatment. Taken together, these findings suggest that 
etifoxine is working through a mechanism that is upstream of inflammasome 
assembly and/or activation, perhaps by inhibiting signaling events during the LPS-
driven TLR4 pathway (Lucas & Maes, 2013; Yang et al., 2020). We then sought to 
measure levels of TNF in human macrophages when pre-treated with etifoxine under 
inflammasome activating conditions. TNF is a potent cytokine that promotes an 
inflammatory state when released, and it has also been shown to stimulate ROS-
mediated caspase-1 activation and subsequent IL-1β secretion (Álvarez & Muñoz-
Fernández, 2013; Ślusarczyk et al., 2018; Yang et al., 2020). We found that pre-
treatment with etifoxine inhibited levels of TNF (Figure 6), which further suggests that 
etifoxine acts as an inhibitor of the LPS-TLR4 mediated signalling cascade (Kattah et 
al., 2017; Yang et al., 2020).  
In addition to altering IL-1β secretion, we aimed to determine if pre-treatment with 
etifoxine inhibited the expression of inflammasome-related genes in vitro in both 
mouse (Figure 7) and human myeloid cells (Figure 8). Recent evidence has shown 
that inflammasome-related genes such as nlrp3 and il-1β are dysregulated in MS 
and that the NLRP3 inflammasome is a plausible therapeutic target in PPMS 
(Malhotra et al., 2020; Vidmar et al., 2019). Pre-treatment with etifoxine decreased 
nlrp3 and il-1β mRNA expression in both species under inflammasome-activating 
conditions, further validating the hypothesis that etifoxine is inhibiting inflammasome 
activation. In human macrophages, we also measured expression of tnf⍺-ip3, a gene 
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encoding the deubiquitinating enzyme A20 (Das et al., 2018; Kattah et al., 2017; 
Voet et al., 2018). A20/TNFAIP3 regulates NF-κB and therefore modulates 
neuroinflammation. Recent evidence has shown that A20/TNFAIP3 deficient mice 
developed an exacerbated form of EAE and displayed a hyperactive inflammasome 
response (Voet et al., 2018). Since A20/TNFAIP3 negatively regulates NF-κB, we 
hypothesized that pre-treatment with etifoxine may increase the expression of tnf⍺-
ip3 and suggest a possible binding partner for etifoxine. In our experiments, tnf⍺-ip3 
mRNA expression was decreased similarly to nlrp3 and il-1β mRNA, thereby 
suggesting that etifoxine is not implementing its anti-inflammatory effect through the 
A20/TNFAIP3-NF-κB-mediated pathway.  
Pre-treatment with etifoxine clearly displayed a potent anti-inflammatory effect in 
mouse and human myeloid cells in vitro.  To confirm that decreased levels of 
cytokines were not merely due to a potential cytotoxic effect of etifoxine, cytotoxicity 
and cell viability assays were performed in both murine- and human-derived 
macrophages. A wide dose range of etifoxine was used and no effect on cytotoxicity 
or cell viability were observed (Figures 9 & 10). 
As stated previously, etifoxine has two known binding partners: TSPO and 
GABAA receptors. Etifoxine was initially discovered as a non-benzodiazepine 
psychoactive drug that was used to treat anxiety, in which it implemented its 
anxiolytic effect by binding directly to both TSPO and GABAA  (Mattei et al., 2019b; 
Schlichter et al., 2000). GABAA receptors are primarily expressed on neurons and 
astrocytes, whereas GABAB receptors are expressed on microglia and macrophages; 
etifoxine does not bind to this receptor sub-type (Magnaghi, 2007; Nuss et al., 2019; 
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Schlichter et al., 2000). GABAergic neurotransmission is also highly associated with 
neurosteroid synthesis; however, microglia are unable to produce steroids due to an 
absence of the CYP11A1 enzyme (Gottfried-Blackmore et al., 2008; Magnaghi, 
2007; Nuss et al., 2019; Owen et al., 2017). Herein, we provide evidence that 
excludes GABAA receptors as a possible mechanism of action for etifoxine (Figure 
11). This was done by blocking GABAA with picrotoxin, which has been proven to be 
a highly effective GABAA antagonist (Bhandage et al., 2019; Crowley et al., 2016; 
Mattei et al., 2019a). In the presence of GABAA inhibition, etifoxine was still potently 
able to significantly decrease inflammasome activity and IL-1β production 
We have demonstrated that pre-treatment with etifoxine in myeloid cells inhibits 
inflammasome activation and subsequent pro-inflammatory cytokine secretion. In 
doing so, we have also provided evidence to suggest that etifoxine is likely inhibiting 
a component of the LPS-driven TLR4 pathway, a upstream target of the 
inflammasome (Lucas & Maes, 2013; Yang et al., 2020). To further investigate this 
hypothesis, a gene array was conducted to determine the expression of 86 
inflammasome-related genes in murine macrophages that have been either 
untreated, inflammasome-activated, or have been pre-treated with etifoxine under 
inflammasome activating conditions (Figures 12-14). The most significant results 
were obtained when comparing the etifoxine pre-treatment condition to the 
inflammasome-only condition (Figure 14) because we were able to gather further 
information to aid in elucidating a possible mechanism of action for etifoxine. A 
relevant gene that was heavily upregulated under etifoxine treatment conditions was 
the caspase recruitment domain 6 (CARD6) gene, which is involved in modulating 
apoptosis as well as NF-κB activation (Dufner et al., 2006; Kao et al., 2015; Wang et 
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al., 2019). Prior findings have shown that CARD6 knockout mice display an elevated 
inflammatory response following spinal cord injury, in which pro-inflammatory 
cytokine release significantly increased as a result of hyperactive NF-κB signalling in 
the absence of CARD6 (Wang et al., 2019). The gene for the AIM2 inflammasome 
was also upregulated, which has been known to play a role in MS disease 
progression along with the NLRP3 and NLRC4 inflammasomes (L. Freeman et al., 
2017; Noroozi et al., 2017). bcl2 and birc2 expression were upregulated as well, in 
which both genes code for proteins that inhibit apoptosis (Igci et al., 2016; Labbé et 
al., 2011). bcl2 encodes for an outer mitochondrial membrane protein that blocks 
apoptosis and it also has an altered expression in MS, which may contribute to 
disease pathology (Igci et al., 2016). birc2 encodes for the cellular inhibitor of 
apopotis protein 1 (cIAP1), which is involved in activating caspase-1 to induce 
inflammasome activation (Labbé et al., 2011). There was a downregulation in the 
gene that encodes the P2RX7 receptor, which is a purinoceptor for ATP influx that 
can result in inflammasome activation (Álvarez & Muñoz-Fernández, 2013; Facci et 
al., 2018; Schroder & Tschopp, 2010b; Thawkar & Kaur, 2019). Recent findings have 
suggested that drugs acting on the P2RX7 receptor are able to inhibit 
neuroinflammation by blocking ATP influx, which can act as a form of therapy in 
diseases such as Alzheimer’s and MS (Thawkar & Kaur, 2019). These alterations in 
inflammasome-associated gene regulation can aid in gaining a further understanding 
of how etifoxine inhibits inflammasome-activation in myeloid cells. While several 
possible mechanims are linked to etifoxine, current investigations are ongoing to 
define a more specific mechanism and determine the exact binding partners of this 
small molecule. 
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In vitro, we have demonstrated that etifoxine decreases pro-inflammatory 
cytokine secretion and inhibits inflammasome activation in myeloid cells derived from 
healthy individuals. However, to further implicate etifoxine as a potential therapeutic 
in the pathological context, we further investigated etifoxine in relation to MS disease 
pathology. MS is characterized by three phenotypes: RRMS, SPMS, and PPMS; in 
which RRMS makes up the majority of the population of people living with MS. The 
majority of DMTs are considered immunomodulatory, and have better clinical 
outcomes in RRMS because they decrease relapse rates and slow the 
progression/accumulation of lesions (Axisa & Hafler, 2016; Garg & Smith, 2015; 
Sand, 2015). Unfortunately, approximately 50% of RRMS patients will transition to 
SPMS, which is characterized by a more progressive and neurodegenerative 
phenotype (Ciotti & Cross, 2018; Even, 2017; Sand, 2015). Once diagnosed with 
SPMS, DMT availability and success exponentially decrease; currently there is only 
one FDA-approved DMT for SPMS (Even, 2017). Since there is a high likelihood of 
disease progression and limited DMT options available, it is important to gain a 
further understanding of SPMS disease pathology in order to improve the quality of 
life of these individuals living with SPMS. There is also increasing evidence that 
supports a role for NLRP3 and inflammasome-related genes in SPMS disease 
progression, especially when considering the increase in microglia activation that 
characterizes SPMS. To determine the potential for etifoxine to influence 
inflammasome activity in SPMS-derived cells, we utilized our resources to conduct 
multiple experiments in SPMS-patient derived monocytes (Best et al., 2019; 
Cosenza-nashat et al., 2009; Jack et al., 2005; Malhotra et al., 2020; Saresella et al., 
2014; Soares et al., 2019). In this series of experiments, LPS treatment was used to 
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activate SPMS-patient derived monocytes in vitro (Gaidt & Hornung, 2017), which 
allowed us to observe a variablity in cytokine secretion between healthy controls and 
SPMS patients (Figure 15). In cells derived from SPMS patients, LPS treatment 
resulted in a significant increase in IL-1β and TNF secretion compared to age and 
sex-matched healthy controls. LPS has been used by itself as a form of alternative 
inflammasome activation in monocytes; this is because moncytes have the ability to 
release pro-inflammatory cytokines in reponse to TLR ligands like LPS without the 
addition of another signal or stimuli (He et al., 2016b). In MS, there was also an 
increased concentration of pro-inflammatory cytokines, specifcally IL-1β and IL-18 in 
MS-patient CSF; ROS production was also increased in individuals with MS, which 
further suggests an upregulated inflammasome response (Barclay & Shinohara, 
2017; Govindarajan et al., 2020; Keane et al., 2018). Therefore, the response 
observed in SPMS-patient derived monocytes is likely the result of a hyperactive 
inflammasome response.  
Lastly, we wanted to determine if pre-treatment with etifoxine is capable of 
inducing an anti-inflammatory effect in SPMS patient-derived PBMCs under 
inflammasome activating conditions. In MS, inflammasomes have been shown to be 
associated with susceptibilty, disease severity, and disease progression; it has also 
been suggested that inhibiting inflammasome activation may act as a form of therapy 
by reducing neuroinflammation (Barclay & Shinohara, 2017; Freeman et al., 2017; 
Freeman & Ting, 2016; Gris et al., 2010; Prins et al., 2013; Voet et al., 2018). Our 
results demonstrate that pre-treatment with etifoxine has an inhibitory effect on IL-1β 
expression in SPMS-patient derived PBMCs under inflammasome activating 
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conditions (Figure 16). This finding can be utilized to further explore the therapeutic 
potential of etifoxine in SPMS.  
Throughout this thesis, I have been able to provide extensive evidence to support 
the proposed hypothesis that the immunomodulatory effect of etifoxine occurs 
through an inhibitory mechanism downstream of inflammasome activation. I have 
shown that pre-treatment with etifoxine is capable of inhibiting inflammasome 
activation in both murine and human derived myeloid cells, which was supported by 
both a decrease in IL-1β secretion as well as a down-regulation in several 
inflammasome-associated genes. Furthermore, I provided evidence in the form of a 
gene array to suggest that etifoxine is likely binding to a component of the 
TLR4/MyD88/NF-kB pathway to inhibit inflammasome activation. Since etifoxine is 
able to decrease inflammasome activation in microglia, further investigations  into 
whether etifoxine is implementing this effect in SPMS (i.e. in vivo), primarily because 
SPMS is characterized by a vast increase in microglia activation and subsequent 
neurodegeneration (Ciotti & Cross, 2018; Mahad et al., 2015; Malhotra et al., 2020). 
Practically, etifoxine is also a desirable option for a therapy because it is currently 
marketed as a form of treatment for psychiatric disorders in Europe and can be 
administered in larger doses without negative side effects (Nuss et al., 2019; 
Schlichter et al., 2000; Simon-O’Brien et al., 2016). The findings of this thesis in 
combination with previous literature allows us to provide clinically relevant evidence 
to support the exploration of etifoxine as a possible form of therapy for SPMS. 
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Chapter 5: Future Directions 
As expected, there are limitations to the current study. The majority of 
experiments were conducted in vitro, therefore these findings may not be 
representative of what occurs in vivo. The inflammasome activation protocol is also 
an exacerbated inflammasome response, which may not reflect the inflammasome-
mediated response that occurs in somatic cells.  
We aim to further explore the elusive function of etifoxine in relation to 
inflammasome activation, specifically in SPMS. First of all, it would be desirable to 
conduct additional ELISA-based experiments in both murine and human derived 
myeloid cells to measure additional cytokines, such as IL-18. An increase in proteins 
measured through western blotting would also provide further validation of the anti-
inflammatory effect mediated by etifoxine, specifically this would include pro-caspase 
1 and ASC. The results of the gene array also can be extensively analyzed; there 
were multiple inflammasome-associated pathways that can be further investigated to 
assist in determining the mechanism of action for etifoxine. Additionally, our 
colleagues are presently completing a clinical trial on TSPO ligand-based therapies 
in MS patients, as well as attempting to determine additional binding partners for 
etifoxine through mass spectrometry. 
In relation to SPMS, we would like to complete a cytokine-profile on PBMCs that 
have been pre-treated with etifoxine under inflammasome activating conditions to 
determine how etifoxine effects SPMS-derived cells in vitro. Furthermore, we can 
assess additional inflammasome-associated factors to further elucidate a mechanism 
of action for etifoxine, such as mitochondrial ROS production.  
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